 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc. 
Evaluation of ACUVUEÂ® OASYS 1-Day for Astigma tism Contact [CONTACT_312778]-6530  Version: 1.0   
Date:  January 2023  
Investigational Products: ACUVUE
Â® OASYS 1-Day for Astigmatism contact [CONTACT_312779]: Astigmatism, senofilcon A, ACUVUEÂ® OASYS 1-Day for Astigmatism contact 
[CONTACT_13276], lidstock, daily wear, daily disposab le, non-dispensing, subjec tive comfort, Visual 
Analog Scale, subject-reported ocular sy mptoms, lens fit, Single use Eye-CeptÂ® Rewetting 
Drops, LacriPure Saline Solution, ScleralF il Preservative Free Saline Solution. 
Statement of Compliance to protocol, GCP and applicable regulatory guidelines: 
This clinical trial will be conducted in compliance with ISO [ZIP_CODE]:2020 Clinical 
investigation of medical devices for human  subjects â€“ Good clinical practice1, and the 
Declaration of Helsinki.2  
Confidentiality Statement: 
This document contains confidential informat ion, which should not be copi[INVESTIGATOR_530], referred to, 
released or published without written approva l from [COMPANY_012] Vision Care, Inc. The 
information may not be disclosed to others except  to the extent necessary  to obtain Institutional 
Review Board/Independent Ethics Committee ap proval and informed consent, or as required 
by [CONTACT_19543], Federal and Stat e Laws, as applicable. Persons to whom this information is 
disclosed must be informed that this informatio n is privileged and confidential and that it 
should not be further disclosed without th e written permission of [COMPANY_012] Vision 
Care, Inc. Any supplemental information that may be added to this document is also 
confidential and proprietary to Johnson & Johns on Vision Care, Inc. and must be kept in 
confidence in the same manner as the contents of this document. 
CR-6530, v 1.0  
Page 1 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 TABLE OF CONTENTS 
PROTOCOL TITLE, NUMBER , VERSION AND DATE...................................................... [ADDRESS_385183] Article Allocation ............................................................................................. 21 
5.2. Masking .................................................................................................................... 22 
5.3. Procedures for Maintaining and Breaking the Masking ........................................... 22 
6. STUDY INTERVENTION ............................................................................................. 22 
CR-6530, v 1.0  
Page 2 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 6.1. Identity of Test Articles ............................................................................................ 22 
6.2. Ancillary Supplies/Products ..................................................................................... [ADDRESS_385184] Articles ................................................................................ 24 
7. STUDY EVALUATIONS .............................................................................................. 25 
7.1. Time and Event Schedule ......................................................................................... 25 7.2. Detailed Study Procedures ....................................................................................... 27 
VISIT 1 ........................................................................................................................... 27 FINAL EVALUATION .................................................................................................. 31 
7.3. Unscheduled Visits ................................................................................................... 32 
7.4. Laboratory Procedures ............................................................................................. 33 
8. SUBJECTS COMPLETION/WITHDRAWAL.............................................................. 33 
8.1. Completion Criteria .................................................................................................. 33 8.2. Withdrawal/Discontinuation from the Study ........................................................... 34 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. [ADDRESS_385185] QUALITY COMPLAINTS ................. 37 
13. ADVERSE EV ENTS ...................................................................................................... 38 
13.1. Definitions and Classifications ................................................................................. 38 13.2. Assessing Adverse Events ........................................................................................ 40 
13.2.1. Causality Assessment........................................................................................ 41 
13.2.2. Severity Assessment ......................................................................................... 41 
13.3. Documentation and Follow-Up of Adverse Events ................................................. 42 
13.4. Reporting Adverse Events ........................................................................................ 43 
13.4.1. Reporting Adverse Events to Sponsor .............................................................. 43 13.4.2. Reporting Adverse Events to the Respons ible IEC/IRB and Health Authorities
[ADDRESS_385186] .......................................................................................... 44 
CR-6530, v 1.0  
Page 3 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 13.6. Reporting of Pregnancy ............................................................................................ [ADDRESS_385187] KEEPI[INVESTIGATOR_1645]/ARCHIVING ................................... 48 
15.1. Electronic Case Report Form/Data Collection ......................................................... [ADDRESS_385188] ......................................................................................................... 48 
15.3. Trial Registration on ClinicalTrials.gov ................................................................... 49 
16. DATA MANAGEMENT................................................................................................ 49 
16.1. Access to Source Data/Document ............................................................................ 49 16.2. Confidentiality of Information ................................................................................. 49 
16.3. Data Quality Assurance ............................................................................................ 49 
16.4. Data Monitoring Committee (DMC) ........................................................................ [ADDRESS_385189] (IEC/IRB) .............. [ADDRESS_385190] RETENTION ................................................................................... 53 
20. FINANCIAL CONSIDERATIONS ............................................................................... 54 
21. PUBLICATION .............................................................................................................. 5 4 
22. REFERENCES ............................................................................................................... 5 4 
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) ..... 56 
CR-6530, v 1.0  
Page 4 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 APPENDIX B: PATIENT INSTRUCTION GUIDE ............................................................. 61 
APPENDIX C: PACKAGE INSE RT (APPROVED PRODUCT) ......................................... 62 
APPENDIX D:  ...................................... [ADDRESS_385191]-REPORTED OCULAR SYMPTOMS................................................ 98  DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTION
............................................................................................................................................... 100 
 BIOMICROSCOPY SCALE .............................................................................. 106 
 DISTANCE AND NEAR VISUAL  ACUITY EVALUATION ......................... 112 
 TORIC FIT EVALUATION ............................................................................... 117 
 LENS INSERTION AND REMOVAL .............................................................. 122 
APPENDIX E:  GUIDELINES FOR COVID-19 RISK MITIGATION ............ 125 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_1783] ........................ [ADDRESS_385192] OF TABLES 
Table 1: Test Articles ........................................................................................................ ...... 22 
Table 2: Ancillary Supplies ................................................................................................... . 23 
Table 3: Time and Events ...................................................................................................... . 25 
Table 4: Disallowed systemic medications ............................................................................. 35 
Table 5: Disallowed syst emic antihistamines ......................................................................... 36 
Table 6: Power Estimates for Different Scenarios of Statistical Tests and Reference Rates . [ADDRESS_385193] OF FIGURES 
Figure 1: Study Flowchart ..................................................................................................... . 14 
CR-6530, v 1.0  
Page 5 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 SYNOPSIS 
Protocol Title Evaluation of ACUV UEÂ® OASYS 1-Day for Astigmatism 
Contact [CONTACT_312780], 7500 Centurion Parkwa y, Jacksonville, FL  [ZIP_CODE] 
Clinical Phase Clinical trial phase: post-market  
Design control phase:  post-marketin g, phase [ADDRESS_385194]: ACUVUEÂ® OASYS 1-Day for 
Astigmatism (AO1DfA) contact [CONTACT_13276]. 
The test lenses will be AO1DfA contact [CONTACT_312781]. The control lenses will be AO1DfA contact [CONTACT_312782].  
Wear and Replacement Schedules Wear Schedule: Daily wear (in-office wear for approximately 1 hour) Replacement Schedule: Dail
y disposable 
Objectives Primary Objective: 
To evaluate the occurrence of subject-reported ocular 
symptoms with AO1DfA manufactured with a new lidstock design against AO1DfA with lega cy lidstock as control.  
Exploratory Objectives: To evaluate subjective comfor t, ocular physiology and lens 
fitting characteristics for AO1DfA manufactured with a new lidstock design against AO1DfA with legacy lidstock as control. 
Study Endpoints Primary endpoint: 
xPercentage of eyes reporting â€˜moderateâ€™ or â€˜severeâ€™subject-reported ocular symptoms reported during
approximately 1 hour of we ar of the study lenses.
Exploratory endpoints: 
xSubjective comfort, as measured using a Visual AnalogScale (VAS), following lens settling and followingapproximately 1 hour of we ar of the study lenses.
xOcular physiology (slit lamp biomicroscopy findings)using the FDA grading scale following approximately 1hour of wear of the study lenses.
xLens fitting characteristics (general fit assessment and
toric fit assessment).
xAdverse Events
CR-6530, v 1.0  
Page 9 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 Study Design This will be a single-visit, randomized, double-masked, 
bilateral wear, non-dispensi ng, 2-sequence Ã— 2-period 
crossover study. Eligible subjects  will be randomized to one of 
two unique lens wear sequences (Test/Control or Control/Test). During each wear period the lenses will be worn bilaterally for approximately one hour in-office. A 15-minute washout period between lenses will be utilized . Subjects will be asked an open-
ended verbal question regarding their ocular symptoms following lens settling, and again following at least 1 hour of wear. Subjective comfort will be  assessed using a Visual 
Analog Scale (VAS). Ocular physiology will be assessed by [CONTACT_312783]. Lenses will be collected and stored for return  to the sponsor after removal.  
 See the flow chart at the end of the synopsis table for the 
schematic of the study visits  and procedures of main 
observations (Fi
gure 1). 
Sample Size This study will have an en rollment target of approximately [ADDRESS_385195] 30 to complete (assuming a 
dropout rate of 10%).  
Study Duration Total study duration (first subject, first vis it to last subject, last 
visit) is anticipated to be approximatel y [ADDRESS_385196] lens wearers 
(either spherical or toric le nses) who are between 18 and 
39 
years of a ge (inclusive).  
CR-6530, v 1.0  
 
Page 10 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 Eligibility Criteria - Inclusion Potential subjects must satisfy al l the following criteria to be 
enrolled in the study.  Inclusion Criteria following Screening 
The subject must:  
1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 
3. Be between 18 and 39 years of ag e (inclusive) at the time of 
screening. 
4. Habitually wear soft contact [CONTACT_94636] (either sphere or toric) in 
both eyes in a daily reusable  or daily disposable wear 
modality (i.e., not extended wear modality).  Habitual wear is defined as a minimum of [ADDRESS_385197]: 6. Have the spherical component of their vertex-corrected 
distance refraction within the range +4.00 to -9.00 DS 
(inclusive) in both eyes. 
7. Have the magnitude of the cylindrical component of their vertex-corrected distan ce refraction below 3.00 DC 
(inclusive) in both eyes. 
8. Have best corrected monocul ar distance VA of 20/30 or 
better in each e
ye. 
CR-6530, v 1.0  
 
Page 11 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 Eligibility Criteria â€“ Exclusion Potential subjects who meet any of the following criteria will 
be excluded from partic ipating in the study. 
 Exclusion Criteria following Screening The subject must not: 
1. Be currently pregnant or lactating. 
2. Be diabetic. 
3. Be currently using any ocular me dications or have an ocular 
infection of any type. 
4. Have any ocular or systemic allergies, disease,  infection, or 
use of medication that might c ontraindicate or interfere with 
contact [CONTACT_312784], including infectious diseases (e.g., hepatitis, 
tuberculosis), contagious im munosuppressive disease (e.g., 
Human Immunodeficiency Viru s [HIV]), or history of 
serious mental illness or seizures. See section 9.[ADDRESS_385198] habitually worn rigid gas permeable (RGP) lenses, 
orthokeratology lenses, or hybr id lenses (e.g., SynergEyes, 
SoftPerm) within the past [ADDRESS_385199] a history of stra bismus or amblyopia. 
8. Be an employee (e.g., Inve stigator, Coordinator, 
Technician) or family me mber of an employee of 
investigational clinic. 
9. Have participated in a contac t lens or lens care product 
clinical trial within [ADDRESS_385200] not: 
10. Have clinically significant (Grade 3 or 4 on the FDA classification scale) slit lamp  findings (e.g. corneal edema, 
neovascularization or staini ng, tarsal abnormalities or 
bulbar injection) or other co rneal or ocular disease or 
abnormalities that may contraindicate cont act lens wear or 
otherwise compromise st udy endpoints (including 
entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, glaucoma, 
history of recurrent corneal er osions, aphakia, moderate or 
above corneal distortion,  herpetic keratitis). 
11. Have fluctuations in vision due to clinically significant dry e
ye or other ocular conditions. 
CR-6530, v 1.0  
 
Page 12 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 12. Have had or have planned (w ithin the study period) ocular 
or intraocular surgery (e.g., radial keratotomy, PRK, 
LASIK, etc.). 
Disallowed Medications/Int erventions  Subjects will not be eligible to enroll if they are taking any ocular medications, or any syst emic medications that would 
normally contraindicate contact [CONTACT_129803]. S ee section 9.1 for details 
re
gardin g disallowed s ystemic medications.  
Measurements and Procedures The key procedures associated  with this study will be: 
- Subjective refraction and meas urement of visual acuity 
- Contact [CONTACT_312785], in cluding measurement of lens 
orientation position using a slit lamp 
- Evaluation of subjectiv e comfort using a VAS 
- Evaluation and grading of oc ular physiology using a slit 
lamp biomicroscope 
- Collection of sub
ject-worn lenses 
Microbiology or Other Laborator
y Testin g None. 
Study Termination The occurrence of an Unanticipated Serious Adverse Device 
Effect ([LOCATION_003]DE) or Serious Adverse Event (SAE) for which a causal relationship to a test ar ticle cannot be ruled out, will 
result in stoppi[INVESTIGATOR_312771]. In 
the event of a [LOCATION_003]DE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of subject(s) and will discuss this with the Principal Investigator [INVESTIGATOR_312772]. 
Ancillary Supplies/ Study-Specific Materials Fluorescein strips and preservati ve-free rewetting drops / saline 
will be supplied for use as need ed. Glass vials will be supplied 
for worn lens collection.  
Principal Investigator(s) and Study Institution(s)/Site(s) A full list of Principal Investig ators, clinical sites, and 
institutions is kept separately  from the Study Protocol and is 
included in the stud
y Trial Master File. 
   
CR-6530, v 1.0  
 
Page 13 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS 
ADE   Adverse Device Effect ADHD   Attention Deficit Hyperactivity Disorder AE   Adverse Event/Adverse Experience AO1DfA
 ACUVUE OASYSÂ® 1-DAY with HydraLuxeâ„¢ TECHNOLOGY for 
ASTIGMATISM 
BSCVA  Best Spectacle Corrected Visual Acuity CFR   Code of Federal Regulations CLUE   Contact [CONTACT_312786]-[ADDRESS_385201] 
HIV   Human Immunodeficiency Virus 
IB   Investigatorâ€™s Brochure ICH   The International Council for Harmonization 
IEC   Independent Ethics Committee 
IRB   Institutional Review Board 
ISO   International Organization for Standardization 
ITT   Intent-to-Treat 
JJVC   [COMPANY_012] Vision Care, Inc. 
LASIK   Laser-Assisted in Situ Keratomileusis 
OD   Right Eye 
OS   Left Eye 
OU   Both Eyes PIG   Patient Instruction Guide PQC   Product Quality Complaint PRK   Photorefractive Keratectomy 
PRO   Patient Reported Outcome 
QA   Quality Assurance SAE   Serious Adverse Event/Serious Adverse Experience 
SAS   Statistical Analysis System
 
SD   Standard Deviation 
UADE   Unanticipated Adverse Device Effect [LOCATION_003]DE  Unanticipated Serious Adverse Device Effect VA   Visual Acuity 
CR-6530, v 1.0  
 
Page 15 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 1. INTRODUCTION AND BACKGROUND 
[COMPANY_012] Vision Care (JJVC) is in troducing a new lidstock for production of 
AO1DfA contact [CONTACT_13276]. The purpose of this clini cal investigation is to evaluate the initial 
clinical performance of AO1DfA lenses manufactured with this new lidstock in terms of 
subject-reported ocular symptoms, subjective comfort, ocular physiology and lens fitting 
characteristics.  
1.1. Name [CONTACT_312809] 1DfA contact [CONTACT_312787]. The test lens will be manufac tured with the new lidstock, and the control 
lenses will be produced using legacy lidstock.  
 Further details about the test articles are found in section [ADDRESS_385202] and control lenses will be supplied in a single 
lens power, subjects will wear a spectacle tr ial frame with compensating prescription (such 
that the total power of the trial frame plus study contact [CONTACT_312788]) over the lenses during wear periods.  
1.3. Summary of Findings from Nonclinical Studies 
Not applicable â€“ marketed product only. 
1.4. Summary of Known Risks and Benefits to Human Subjects 
Subjects are not anticipated to receive any direct clinical benefit from participating in this study; however, results of the study will be be neficial in gathering clinical data on the 
performance of AO1DfA contact [CONTACT_312789].  No adverse device effects, residua l risks, or interactions with concomitant medical treatments 
are anticipated, beyond those nor mally associated with regular soft contact [CONTACT_13279].  
 Comprehensive clinical information regardi ng the AO1DfA lens is given in the AO1DfA 
package insert (Appendix C). 
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical Study 
AO1DfA lenses are FDA-approved and marketed worldwide. There have been no previous clinical evaluations of AO1DfA lenses ma nufactured with the alternative lidstock.  
 
CR-6530, v 1.0  
 
Page 16 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 For further details data related to the AO1D fA lens, refer to the AO1DfA package insert 
(Appendix C).   
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES 
2.1. Objectives  
Primary Objective To evaluate the occurrence of subject-reporte d ocular symptoms with AO1DfA manufactured 
with a new lidstock design against AO1Df A with legacy lidstock as control.  
 Exploratory Objectives To evaluate subjective comfort, ocular physiolo gy and lens fitting characteristics for AO1DfA 
manufactured with a new lidstock design agains t AO1DfA with legacy lidstock as control. 
2.2. Endpoints  
Primary endpoint: 
1. Percentage of eyes with â€˜m oderateâ€™ or â€˜severeâ€™ subject -reported ocular symptoms  
 Frequency and severity by [CONTACT_129808]-reported ocular sy mptoms and problems with the 
study lens following lens settling and again following at least 1 hour of bilateral study lens 
wear. Severity of the symptoms can be: 
x 0 = Not Applicable or Not Recorded; 
x 1 = Mild and results in little or  no interference with lens wear; 
x 2 = Moderate AND/OR occasionally  interferes with lens wear; 
x 3 = Severe AND/OR frequently interferes with lens wear. 
 Exploratory endpoints : 
1. Adverse Events  
 
2. Subjective Comfort  
A Visual Analog Scale (VAS) will be used to  evaluate subjective comfort following lens 
settling and again following at least 1 hour of bilateral study lens wear . The VAS questionnaire 
will be completed electronically using the following wording:    
Below is a comfort scale with a moveable slider. The right end of the scale (100) represents the best comfort imaginable (you are completely unaware of the lenses). The left end of the 
scale (0) represents the worst comfort imaginabl e (the lenses are completely intolerable). 
Please move the slider to  indicate your response. 
How comfortable are the contac t lenses you're wearing? 
 
3. Ocular Physiology 
Ocular physiology will be assessed  for each subject eye at baseline, after at least 1 hour of 
bilateral study lens wear and at any unscheduled visit using the FDA Grading scale (Grade 
CR-6530, v 1.0  
 
Page 17 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 0=None, Grade 1=Trace, Grade 2=Mild, Grade 3=Moderate, Grade 4=Severe). Slit lamp 
finding assessments include the following categories: 
x Corneal Infiltrates (Yes/No) 
x Corneal Edema 
x Corneal Neovascularization 
x Corneal Neovascularization Location 
x Corneal Staining 
x Corneal Staining Location 
x Conjunctival Injection 
x Tarsal Abnormalities 
x Other 
 
4. Lens fitting characteristics (general fit assessment and toric fit assessment).  
Lens fitting characteristics will be assessed fo r each eye at least [ADDRESS_385203]. Toric fitting characteristics that will be assessed are lens orientation and orientation stability with blinks.   
 
2.3. Hypotheses 
All endpoints will be analyzed descriptively; no fo rmal hypotheses will be tested in relation to 
study endpoints. 
3. TARGETED STUDY POPULATION 
3.1. General Characteristics  
The target population for this study will be heal thy adult soft contact [CONTACT_19554] (either 
spherical or toric wearers) between 18 and 39 years of age (inclusive).   
3.2. Inclusion Criteria 
Potential subjects must satisfy all of the follo wing criteria to be enrolled in the study: 
 
Inclusion Criteria following Screening 
The subject must:  
1. Read, understand, and sign the STATEM ENT OF INFORMED CONSENT and 
receive a fully executed copy of the form. 
2. Appear able and willing to adhere to the inst ructions set forth in this clinical protocol. 
3. Be between 18 and 39 years of age (inc lusive) at the time of screening. 
4. Habitually wear soft contact [CONTACT_13276] (either sphere or tori c) in both eyes in a daily 
reusable or daily disposable wear modality (i .e., not extended wear modality).  Habitual 
wear is defined as a minimum of [ADDRESS_385204] four weeks. 
CR-6530, v 1.0  
 
Page 18 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 5. Possess a wearable pair of spectacles that  provide correction fo r distance vision. 
 Inclusion Criteria at Baseline Evaluation 
The subject must: 
6. Have the spherical component of their vert ex-corrected distance refraction within the 
range +4.00 to -9.00 DS (inclusive) in both eyes. 
7. Have the magnitude of the cy lindrical component of their vertex-corrected distance 
refraction below 3.00 DC (inclusive) in both eyes. 
8. Have best corrected monocular distan ce VA of 20/30 or better in each eye.  
3.3. Exclusion Criteria 
Potential subjects who meet any of the following criteria will be excluded from participating 
in the study:  
 Exclusion Criteria following Screening The subject must not: 
1. Be currently pregnant or lactating. 
2. Be diabetic. 
3. Be currently using any ocular  medications or have an oc ular infection of any type. 
4. Have any ocular or systemic allergies, di sease, infection, or us e of medication that 
might contraindicate or interf ere with contact [CONTACT_312790], including infectious diseases (e.g., hepatitis, tuberculosis), contagious 
immunosuppressive disease (e .g., Human Immunodeficiency Virus [HIV]), or history 
of serious mental illness or seizures. See section 9.[ADDRESS_385205] habitually worn rigid gas permeable  (RGP) lenses, orthokeratology lenses, or 
hybrid lenses (e.g., SynergEyes, Soft Perm) within the past [ADDRESS_385206] a history of stra bismus or amblyopia. 
8. Be an employee (e.g., Investigator, Coordinato r, Technician) or family member of an 
employee of invest igational clinic. 
9. Have participated in a contact [CONTACT_71170] [ADDRESS_385207] not: 
10. Have clinically significant (G rade 3 or 4 on the FDA clas sification scale) slit lamp 
findings (e.g. corneal edema, neovascularization or staini ng, tarsal abnormalities or 
bulbar injection) or other corneal or ocular disease or abnormalities that may contraindicate contact [CONTACT_312791] (including 
entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], chalazia, recurrent styes, glaucoma, history of recurrent corneal 
erosions, aphakia, moderate or above co rneal distortion, he rp
 etic keratitis). 
CR-6530, v 1.0  
 
Page 19 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 11. Have fluctuations in vision due to clinically significan t dry eye or other ocular 
conditions. 
12. Have had or have planned (within the study pe riod) ocular or intraocular surgery (e.g., 
radial keratotomy, PRK, LASIK, etc.).  
3.4. Enrollment Strategy 
Study subjects will be recruited from the Institution/clinical si teâ€™s subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved 
materials.  
4. STUDY DESIGN AND RATIONALE 
4.1. Description of Study Design 
This will be a single-visit, randomized, doubl e-masked, bilateral wear, non-dispensing, 2Ã—2 
crossover study. Eligible subjects will be randomi zed into one of two unique sequences, to 
wear two different study lenses, one at a time , over two wear periods (test then control or 
control then test). During each wear period the le nses will be worn bila terally for at least one 
hour in-office. Subjective co mfort will be assessed using a Visual Analog Scale (VAS). 
Subjects will be asked an open-ended verbal question regarding their ocular symptoms 
following lens settling and again following at least 1 hour of w ear. Subjective comfort will be 
assessed using a Visual Analog Scale (VAS). Oc ular physiology will be assessed by [CONTACT_312792]. Lenses  will be collected and stored for return to 
the sponsor after removal. Subjects will not  have access to the study lenses following 
completion of the study.  
4.2. Study Design Rationale 
A single-visit, non-dispensing, 2x2 crossover stu dy design was chosen as the optimal design 
to assess the primary and secondary study objecti ves. Crossover designs are a well-established 
study design in which subjects are exposed to multiple treatments during different time periods. 
The design is cost effective and more efficien t since between-subject variability is minimized. 
Moreover, randomization removes potential for syst ematic error or bias and balances both the 
known and unknown confounding factors that  may affect the study outcomes. 
 Each lens will be worn for a pproximately 1 hour (in- office), which is co nsidered a sufficient 
length of time to evaluate the clinical endpoints of interest (i nitial comfort, subject-reported 
ocular symptoms, lens fit and oc ular physiology). As both wear pe riods will be completed at a 
single visit, to help reduce the potential risk  of treatment carryover  effects, a 15-minute 
washout period between lenses will  be utilized. Furthermore, sin ce the primary objective is to 
assess ocular symptoms, rewetting drops will be in stilled in each eye between lenses, to further 
washout any residual effects subjects may be experiencing from their previous lens. 
CR-6530, v 1.0  
 
Page 20 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 4.3. Enrollment Target and Study Duration 
This study will have an enrollment target of [ADDRESS_385208]; total study duration (first subjec t, first visit to last 
subject, last visit) including the enrollment period is expected  to be approximately [ADDRESS_385209] lens fitting at visit 1, eligible subjects will be 
randomized to one of two uni que lens wear sequences using a computer-generated 
randomization scheme provided by [CONTACT_312793]. Permuted  block randomization 
will be used to avoid bias in the assignment of subjects to treatment, and to enhance the validity 
of statistical comparisons across treatment groups. Each block will contain two different lens trial sequences. The randomization scheme will be generated using the PROC PLAN procedure 
from Statistical Analysis System (SAS) Softwa re Version 9.4 or higher (SAS Institute, Cary, 
NC)
5.[ADDRESS_385210] occurred prior to 
randomization:  
â€¢ Informed consent must have been obtained.  
â€¢ The subject must have met all eligibility criteria. 
â€¢ The subjectâ€™s screening a nd baseline information must have been collected.  
 When fitting test articles, the following steps should be followed to maintain randomization 
codes: 
1. Investigator or designee (documented on the Delegation Log) will consult the lens 
fitting schedule to obtain the test article as signment for that subjec t prior to dispensing. 
2. Investigator or designee will record the subj ectâ€™s number on the appropriate line of the 
randomization (lens fitting) schedule. 
3. Investigator or designee will pull the appr opriate test articles from the study supply. 
All test articles that are opened, whether dispensed (placed/fit on eye or dispensed 
outside the clinical site) or not, must be recorded on the Test Article Accountability 
Log in the â€œDispensedâ€ section. 
CR-6530, v 1.0  
 
Page 21 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 6.4. Packaging and Labeling 
The test articles will be packaged in blisters  as the primary packaging. Th e test article will be 
supplied in standard production packagi ng. A sample study label is shown below: 
 
Primar y Packa ging Secondar y Packa ging 
  
6.5. Storage Conditions 
Test articles will be maintained at ambient temper atures at the clinical site. Test articles must 
be kept under secure conditions. 
6.6. Collection and Storage of Samples 
Worn study lenses will be collected as part of the study procedures. Following removal, each 
worn lens will be placed individually into one of the supplied glass vi als. Lenses are to be 
stored dry, i.e., without any solution. The supp lied cap will be screwed onto the vial, and the 
vial will be labelled with th e subject number, eye (OD or OS),  and randomization code. Lenses 
will then immediately be placed into a fre ezer prior to transfer back to JJVC.  
 In addition to the collection procedures above, when  possible, any lens or test article associated 
with an Adverse Event and/or a Product Quality Complaint must be retained and stored in a 
glass vial with moderate solutio n pending directions from the s ponsor for potenti al return to 
JJVC. 
6.7. Accountability of Test Articles 
JJVC will provide the Investigator with sufficient quantities of study articles and supplies to complete the investigation. The Investigator is asked to retain all lens shipment documentation for the test article a ccountability records.  
 
CR-6530, v 1.0  
 
Page 24 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 8.2. Withdrawal/Discontinua tion from the Study 
A subject will be withdrawn from the st udy for any of the fo llowing reasons: 
x Subject withdrawal of consent. 
x Subject not compliant to protocol. 
x Subject lost to follow-up. 
x Subject no longer meets elig ibility criteria (e .g. the subject becomes pregnant). 
x Subject develops significant or serious adve rse events necessitating discontinuation of 
study lens wear. 
x Subjects who have experienced a Co rneal Infiltrativ e Event (CIE). 
x Investigatorâ€™s clinical judgment regarding the subject safety reasons (that it is in the 
best interest of the subject to stop treatment). 
x Subject not compliant with study lens wear schedule.  
x Subject not successfully dispensed due to lack  of efficacy or safety (e.g., poor vision, 
poor comfort, or unacceptable fit).  
For discontinued subjects, the Investigator will: 
x Complete the current visit (s cheduled or unscheduled). 
x Complete the Final Evaluation, indicating th e reason that the subject was discontinued 
from the study. 
x Record the spherocylindrical refraction with  best corrected distance visual acuity. 
x Collect used test article(s) (worn or brought to the visit)  from the subject and discard 
them, unless otherwise stated in section 7.2. 
x Collect all unused test article(s) from the subject. 
x Make arrangements for subject care, if needed, due to their study participation. 
 
Additional subjects may be enrolled if a subj ect discontinues from th e study prematurely.  
 In cases where a subject is lost to follow-up, ev ery possible effort must be made to contact [CONTACT_312794]/withdrawal. Th e measures taken to follow 
up must be documented including two written attemp ts and a certified letter (or equivalent) as 
the final attempt.  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION 
Concomitant medications will be documented during screening and updated during the study. 
Disallowed concomitant interventions for this study include ocular medications of any kind, 
or any systemic medications that would norma lly contraindicate contact  [CONTACT_126102]. 
9.1. Systemic Medications 
Certain systemic medications are known to have  a higher likelihood to interfere with contact 
[CONTACT_13279], chiefly by [CONTACT_312795].  
CR-6530, v 1.0  
 
Page 34 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 The Sponsor will determine when a study will be stopped. The Principal Investigator [INVESTIGATOR_312773]â€™s re sults are compromised. 
 JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The study can be terminated by [CONTACT_312796] i ndividual clinical  site due to 
specific clinical observations, if in their opi[INVESTIGATOR_1649], after a discussion with JJVC, it is determined 
that it would be unwise to continue at the clinical site.  JJVC (and the IEC/IRB and  DMC, if applicable) will evaluate  all adverse events. If it is 
determined that an adverse event presents an un reasonable risk, the inves tigation, or that part 
of the investigation presenting the risk, will be terminated as soon as possible. 
 Should the study be terminated (either prematurely or as scheduled), the Investigator will notify the IEC/IRB and Regulator y Authority as required by [CONTACT_312797]. 
12. PROCEDURE FOR HANDLING PR ODUCT QUALITY COMPLAINTS 
A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication 
that alleges deficiencies rela ted to the identity, quality, durability, reliability, safety, 
effectiveness or performance of test articles after th ey have been released for clinical trial use.   
 Potential complaints may come from a variety of  sources including but no t limited to subjects, 
clinical research associates (CRA), clinical operations managers (C OM), medical monitors, 
and site personnel, etc. The following are not considered product  quality complaints: 
x Subject satisfaction inquiries reported vi a â€œSubjective Questionna iresâ€ and â€œPatient 
Reported Outcomes (PRO).â€ 
x Clinical test articles that are stored imp roperly or damaged after receipt at the 
investigational site. 
x Lens replacements that occu r due to drops/fall-outs. 
x Damage deemed by [CONTACT_35513], 
and not indicative of a quality de ficiency (i.e. tears, rips, et c.), only in situations where 
there is no deficiency alleged by [CONTACT_423]. 
 Within [ADDRESS_385211] be 
recorded in the EDC system, which will trig ger an automatic email notification to the 
appropriate COM/CRA and Clinical QA representa tive. In cases where the EDC system in use 
is not configured to send automatic notificatio ns or when an EDC system is not used, the 
COM/CRA is responsible for not ifying Clinical QA upon discovery that a PQC has occurred.   
 Upon receipt of the EDC notification, the COM/ CRA will contact [CONTACT_312798]:  
CR-6530, v 1.0  
 
Page 37 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 x Date the complaint was received/recorded  in the EDC System  (Date of Sponsor 
Awareness). 
x Who received the complaint. 
x Study number. 
x Clinical site information (contact [CONTACT_2300], site ID, telephone number). 
x Lot number(s). 
x Unique Subject Identifier(s). 
x Indication of who first observed co mplaint (site personnel or subject). 
x OD/OS indication, along with whether the lens was inserted. 
x Any related AE number if applicable. 
x Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, resolution of symptoms, etc.). 
x Eye Care Provider obje ctive (slit lamp) findings if applicable. 
x Confirmation of product availabil ity for return (and tracking  information, if available), 
or rationale if product is not available for return  
 
 
Once a complaint is received, it will be asse ssed by [CONTACT_19569], CRA, or trained site personnel 
to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or trained site personnel will follow section 13 of this 
protocol. If the AE/SAE was potentially the resu lt of a product quality related deficiency, these 
procedures also apply and will be executed in parallel.    In some cases, a PQC form may be generated in EDC by [CONTACT_35514].  In this event, the 
PQC forms will be marked â€œIntentionally Left Blankâ€ or â€œILBâ€.  Justification for ILB must be documented. 
13. ADVERSE EVENTS 
13.1. Definitions and Classifications 
Adverse Event (AE) â€“ An AE is â€œany untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including ab normal laboratory findings) in subjects, users 
or other persons, whether or not related to th e investigational medica l device and whether 
anticipated or unanticipated.â€  
Note : This definition includes events related to the investigational medical device or the 
comparator, and to the procedures involved. Fo r users or other persons , this definition is 
restricted to events related to investigational medical devices.1 
 
An AE includes any condition (including a pre-existing condition) that: 
1. Was not present prior to the study, but appear ed or reappeared fo llowing initiation of 
the study. 
CR-6530, v 1.0  
 
Page 38 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 2. Was present prior to the study but worsened  during the study. This would include any 
condition resulting from concomitant illnesses,  reactions to concomitant medications, 
or progression of disease states. 
Note : Pregnancy must be documented as an adverse event and must be reported to the clinical 
monitor and to the Sponsor immedi ately upon learning of the event. 
 Serious Adverse Event (SAE) â€“ An SAE is any adverse event that led to any of the following: 
x Death 
x Serious deterioration in the h ealth of the subject that resu lted in any of the following: 
x Life-threatening il lness or injury 
x Permanent or persistent impairment of a body structure or a body function 
x Hospi[INVESTIGATOR_93790] 
x Medical or surgical intervention to prev ent life-threatening illness or injury or 
permanent impairment to a body structure or a body function. 
x Chronic disease 
x Foetal distress, foetal death or a congen ital physical or mental impairment of birth 
defect. 
 Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not limited to: 
x Microbial Keratitis (MK) 
x Iritis (including cells in the anterior chamber) 
x Permanent decrease in best sp ectacle corrected visual acuity equivalent to 2 acuity lines 
or greater 
x Central Corneal Opacity 
x Central Corneal Neovascularization 
x Uveitis 
x Endophthalmitis 
x Hypopyon 
x Hyphemia 
x Penetration of Bowmanâ€™s Membrane 
x Persistent Epi[INVESTIGATOR_32958] 
x Limbal cell Damage leadi ng to Conjunctivalization 
 Significant Adverse Events  â€“ are defined as events that are symptomatic and warrant 
discontinuation (temporary or perman ent) of the contact [CONTACT_312799], but 
not limited to the following: 
x Contact [CONTACT_35516] (CLPU) 
x Significant Infiltrative Events (SIE) 
x Superior Epi[INVESTIGATOR_312774] (SEALs) 
x Any Temporary Loss of > 2 Lines of BSCVA 
CR-6530, v 1.0  
 
Page 39 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 x Other grade [ADDRESS_385212] lens related co rneal events - e.g. Epi[INVESTIGATOR_19533] (EKC) 
x Asymptomatic Corneal Scar 
x Any corneal event which necessitates te mporary lens discontinuation > 2 weeks 
 Non-Significant Adverse Events  â€“ are defined as those events that are usually asymptomatic 
and usually do not warrant discon tinuation of contact [CONTACT_35517] a reduction in 
wear time.  However, the Investigator may choose to prescribe treatment as a precautionary measure.    Diagnoses and conditions that are considered Oc ular Non-Significant Adverse Events include, 
but not limited to the following: 
x Non-significant Infiltrative Event (NSIE) 
x Contact [CONTACT_19573][INVESTIGATOR_19534] (CLPC) 
x Superficial Punctate Keratitis (SPK) 
x Conjunctivitis: Bacterial, Viral, Allergic 
x Blepharitis 
x Meibomianitis 
x Contact [CONTACT_32984] 
x Localized Allergic Reactions 
x Any corneal event not explicitly defined as serious or significant adverse event, which 
necessitates temporary lens  discontinuation < [ADDRESS_385213] (ADE) â€“ An ADE is an â€œadverse even t related to the use of an 
investigational medical device.â€ 
NOTE 1 : This definition includes adverse events resulting from insufficient or inadequate 
instructions for use, deploymen t, implantation, installation, or  operation, or any malfunction 
of the investigational medical device. NOTE 2 : This definition includes any event resulting from use error or from intentional misuse 
of the investigational medical device.
[ADDRESS_385214] (UADE) â€“ A UADE is any seri ous adverse effect on 
health or safety or any life-t hreatening problem or death caused by, or associated with, the test 
article, if that effect, problem, or death was no t previously identified in nature, severity, or 
degree of incidence in the inve stigational plan, Investigatorâ€™s  Brochure or protocol, or any 
other unanticipated serious problem  associated with the test artic le that relates to the rights, 
safety and welfare of subjects. 
13.2. Assessing Adverse Events 
In conjunction with the medical monitor, the Inves tigator will evaluate adverse events to ensure 
the events are categorized correctly. Elements of categorization will include: 
x Seriousness/Classifications (s ee definition in section 13.1). 
CR-6530, v 1.0  
 
Page 40 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 x Causality or Relatedness â€“ i.e. the relations hip between the test article, study treatment 
or study procedures and the adverse even t (not related, unlikely related, possibly 
related, or related - see de finition in section 13.2.1). 
x Adverse Event Severity â€“ Adverse event seve rity is used to assess the degree of 
intensity of the adverse event (mild, moderate , or severe - see definition in section 
13.2.2). 
x Outcome â€“ not recovered or not resolve d, recovering or resolving, recovered or 
resolved with sequelae, rec overed or resolved, death rela ted to adverse event, or 
unknown. 
x Actions Taken â€“ none, temporarily discontinue d, permanently disc ontinued, or other. 
13.2.1. Causality Assessment 
Causality Assessment â€“ A determination of the relationshi p between an adverse event and the 
test article. The test article  relationship for each adverse event should be determined by [CONTACT_19575]: 
x Not Related- An adverse event that is not related to the use of the test article, study treatment or study procedures. 
x Unlikely Related â€“ An adverse event for which an alternative explanation is more likely, e.g. concomitant treatmen t, concomitant disease(s), or  the relationship of time 
suggests that a causal rela tionship is not likely. 
x Possibly Related â€“ An adverse event that might be due to the use of the test article, or 
to the study treatment or study procedures. An alternative ex planation, e.g. concomitant 
treatment, concomitant disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship cannot be excluded. 
x Related â€“ An adverse event that is listed as a possible adverse effect  (device) or adverse 
reaction (drug) and cannot be reasonably e xplained by [CONTACT_4867], e.g. 
concomitant treatment of concomitant dis ease(s). The relationship in time is very 
suggestive, e.g. it is confirmed by [INVESTIGATOR_5328]-challenge and re-challenge. 
13.2.2. Severity Assessment 
Severity Assessment â€“ A qualitative assessment of the degr ee of intensity of an adverse event 
as determined by [CONTACT_19577]/her by [CONTACT_423]. The assessment of severity is made irresp ective of test article, st udy treatment or study pr ocedure relationship or 
seriousness of the event and should be eval uated according to the following scale: 
x Mild â€“ Event is noticeable to the subject but  is easily tolerated and does not interfere 
with the subjectâ€™s daily activities. 
x Moderate â€“ Event is bothersome, possibl e requiring additional therapy, and may 
interfere with the subj ectâ€™s daily activities. 
x Severe â€“ Event is intolerable, necessitates additional therapy or alteration of therapy 
and interferes with the subjectâ€™s daily activities. 
CR-6530, v 1.0  
 
Page 41 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 13.3. Documentation and Follow-Up of Adverse Events 
The recording and documenting of adverse even ts (ocular and non-ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure.  Adverse events 
reported before the use of test article, start of study treatment, or study procedures will be 
recorded as medical history. However, if the co ndition deteriorates at any time during the study 
it will be recorded and reported as an AE. Untowa rd medical events reported after the subjectâ€™s 
exit from the study will be record ed as adverse events at the discretion of the Investigator. 
 Upon finding an adverse event, the Principal In vestigator will documen t the condition in the 
subject record and in the eCRFs and complete the Adverse Event eCRF.   
 Complete descriptions of all adverse events must be available in the subject record. All Adverse Events including local and systemic re actions not meeting the criteria for â€œserious 
adverse eventsâ€ shall be captured on the appropriat e case report form or electronic data system. 
All adverse events occurring wh ile the subject is enrolled in  the study must be documented 
appropriately regardle ss of relationship.   
 It is the Investigatorâ€™s responsib ility to maintain docu mentation of each repo rted adverse event. 
All adverse events will be follow ed in accordance with applicab le licensing requirements. Such 
documentation will include the following: 
x Adverse event (diagnosis not symptom). 
x Drawings or photographs (whe re appropriate) that deta il the finding (e.g., size, 
location, and depth, etc.). 
x Date the clinical site was notified. 
x Date and time of onset. 
x Date and time of resolution. 
x Adverse event classification, severity, and re lationship to test arti cles, as applicable. 
x Treatment regimen instituted (where appropr iate), including concomitant medications 
prescribed, in accordance with a pplicable licensing requirements. 
x Any referral to another hea lth care provider if needed. 
x Outcome, ocular damage (if any). 
x Likely etiology. 
x Best corrected visual acuity at the disc overy of the event and upon conclusion of the 
event, if the AE is related to the visual system. 
 Upon discovery of an AE that is deemed â€˜possibly relatedâ€™ or â€˜r elatedâ€™ to the te st article or 
study procedures (whether related to the visu al system or not), an AE review form  
must be completed. Additional dated and initi aled entries should be made at follow-up 
evaluations. Separate forms must be completed for each eye if the AE is bilateral.  
 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the 
infection is microbial in nature. If cultures are collected, the date of culture collection and laboratory utilized will be recorded.  
CR-6530, v 1.0  
 
Page 42 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
  Changes in the severity of an AE shall be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as 
intermittent require documentation of the onset and duration of each ep isode. Changes in the 
assessment of relationship to  the Test Article shall al so be clearly documented. 
 
Subjects who present with an adverse event sh all be followed by [CONTACT_737], within 
licensure, until all signs and symptoms have retu rned to pre-treatment status, stabilized, or 
been satisfactorily reso lved. If further treatment beyond licens ure is required, the patient will 
be referred to the appropriate health care provi der. The Investigator wi ll use his/her clinical 
judgment as to whether a subject reporting with  an adverse event will continue in the study. If 
a subject is discontinued from th e study, it will be the responsibil ity of the Inve stigator to 
record the reason for discontin uation. The Investigator will al so document the adverse event 
appropriately and complete the Adverse Ev ent eCRF. Any subjects with ongoing adverse 
events related to the test articl e, study treatment or study procedures, as of  the final study visit 
date, should be followed  to resolution of the adverse event or until referral to an appropriate 
health care provider, as recommended by [CONTACT_57748]. Non-ocular adverse events that are 
not related to the test articl e, study treatment, or study proc edures may be recorded as 
â€œongoingâ€ without fu rther follow-up. 
13.4. Reporting Adverse Events  
The Investigator will not ify the Sponsor of an adverse even t by e-mail, facsim ile, or telephone 
as soon as possible and no later than 24 hours fr om discovery for any serious /significant 
adverse events, and 2 days from discovery for a ny non-significant adverse event. In addition, 
a written report will be submitted by [CONTACT_163080]/IRB according to 
their requirements (section 13.4.2). The report will comment whether the adverse event was 
considered to be related to the test article, study treatment or study procedures. 
13.4.1. Reporting Adverse Events to Sponsor 
Serious/Significant Adverse Events The Investigator will inform th e sponsor of all serious/signif icant adverse events occurring 
during the study period as soon as possible by e-mail or telephone , but no later than 24 hours 
following discovery of the event. The Inves tigator is obligated to pursue and obtain 
information requested by [CONTACT_312800]. All 
subjects experiencing a serious/significant advers e event must be followed up and all outcomes 
must be reported.  When medically necessary, the Investigator may break the randomization code to determine the identity of the treatment that the subject received. The Sponsor and study monitor should 
be notified prior to unmasking the test articles.  In the event of a serious/significant a dverse event, the Investigator must: 
x Notify the Sponsor immediately. 
CR-6530, v 1.0  
 
Page 43 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 x Obtain and maintain in the subjectâ€™s reco rds all pertinent medical information and 
medical judgment for colleagues who assist ed in the treatment and follow-up of the 
subject. 
x Provide the Sponsor with a complete case hi story which includes a statement as to 
whether the event was or was not relate d to the use of the test article. 
x Notify the IEC/IRB as required by [CONTACT_6179]/IRB reporting pro cedure according to 
national regulations. 
 
Unanticipated (Serious) Adverse Device Effect (UADE) In the event of an Unanticipated (Serious) A dverse Device Effect (UADE), the Investigator 
will submit a report of the UADE to  the Sponsor and IEC/IRB as soon as possible, but no later 
than [ADDRESS_385215] report the results of the 
evaluation to FDA, the IEC/IRB and participati ng Investigators within [ADDRESS_385216]. 
 Non-Serious Adverse Events All non-serious adverse events, including non-seri ous adverse device effe cts, will be reported 
to the sponsor by [CONTACT_312801] 2 days from discovery. 
13.4.2. Reporting Adverse Events to the Respon sible IEC/IRB and He alth Authorities 
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRBâ€™s written guidelines. Each clinical site will refer to and follow any guidelines set forth 
by [CONTACT_19581]/IRB. Each clinical site w ill refer to and follow any guidelines set forth 
by [CONTACT_19582]. 
 The Sponsor will report a pplicable Adverse Events to the lo cal health author ities according to 
the written guidelines, incl uding reporting timelines.  
13.5. Event of Special Interest 
None. 
13.6. Reporting of Pregnancy 
Subjects reporting pregnancy (by [CONTACT_6270]-report) dur ing the study will be discontinued after the 
event is recorded as an Adverse Event. Once discontinued, pregnant participants and their 
fetuses will not be monitored for study rela ted purposes. Pregnant participants are not 
discontinued from contact [CONTACT_71179], but due to general concerns relating to pr egnancy and contact [CONTACT_19584]. Specifically, pregnant women are 
discontinued due to fluctuations in refractive error and/or visual acuity that occur secondary to systemic hormonal changes, and not due to unforeseen health ri sks to the mother or fetus. 
CR-6530, v 1.0  
 
Page 44 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 14. STATISTICAL METHODS 
14.1. General Considerations 
Statistical Analysis will be undertaken by [CONTACT_941] s ponsor or under the authority of the sponsor. A 
general description of the statisti cal methods to be implemented in this clinical trial is outlined 
below.   
 All data summaries and statistical analyses will  be performed using the SAS software Version 
9.4 or higher (SAS Institute, Cary, NC).
[ADDRESS_385217]/eye will be used when available fo r summarization and statistical analysis. 
 Summary tables (descriptive statistics and/or frequ ency tables) will be provided for all baseline 
variables, efficacy variables a nd safety variables as appropriat e. Continuous variables will be 
summarized with descriptive statistics (n, mean , standard deviation (SD), median, minimum, 
and maximum). Frequency count and percentage of subjects or eyes within each category will be provided for categorical data.  Summaries will be presented separately by [CONTACT_312802] (Safety Population, Per-Protocol 
Population, and Intent-to-Treat, when appr opriate) and as described in section 14.3.  
14.2. Sample Size Justification 
This study was not designed or powered to test any statistical hypotheses as this will be the 
first time the Test lens is clinically evaluate d, hence there was no historical data available for 
these lenses. While the Control lens has been evaluated in previous cl inical trials, ocular 
symptoms following lens settling are not typi[INVESTIGATOR_312775]. Th erefore, The sample size was 
chosen by [CONTACT_312803][INVESTIGATOR_312776]. 
 While there are no planned analyses, a power an alysis was performed for the percentage of 
â€œModerateâ€ or â€œSevereâ€ ocular sy mptoms following lens settling and after at least [ADDRESS_385218] for 
statistical difference between study lenses based on 30 subjects to complete. Power 
calculations were performed us ing SAS Software Version 9.4. Moderate and Severe ocular 
symptoms were converted to a binary response as Ü» = [ADDRESS_385219] eye reported a moderate 
or severe ocular symptom and Ü» = [ADDRESS_385220], and between lenses. A total of 2000 
replicating trials were simulated with different scenarios of reference rates. Given the rare event moderate or severe ocular symptoms each replicated sample was analyzed using a 
Bayesian beta-binomial model with correlated binary data (Diniz et al; 2010).
6,7 For each 
simulated trial, the upper bound of the 95% central posterior credible interval constructed for the percentage of moderate and severe ocular symptoms for each  lens and was compared to a 
margin of 5%. Additionally, the upper bound of the 95% central posterior credible interval  for 
CR-6530, v 1.0  
 
Page 45 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 the difference between study lenses, with respec t to the percentage of  moderate and sever 
ocular symptoms was compared  to a margin of 2.5%.  
 
Table 6, below displays different scenarios of statistical tests and effect sizes. Two power 
analyses were performed as both the rate of overall prevalence for each lens as well as the 
difference between rates is encompassed within the primary objective. Furthermore, the power 
estimates were calculated using two credible inte rval levels (90 and 95), to ensure that the 
power for [ADDRESS_385221] to testing for statistical differences (i.e., upper bound of CrI < 2.5%), for the power to detect an effect size of 0.5% there was at l east 79% of the estimated 95% CrIs w ith the upper 
bound being below 2.5%. With respect to testing for statistical superior ity (i.e., upper bound 
of CrI < 5%), for the power to detect an effect size of 0.5% for each lens, there was at least 92% of the estimated 95% CrIs with  the upper bound being below 5%.    
  Table 6: Power Estimates for Different Scenario s of Statistical Tests and Reference Rates  
 
Statistical Test  Effect Size (%) Credible Interval level 
(%) Power 
(%) 
Difference ( ÝŒà¯à¯˜à¯¦à¯§â€“ ÝŒà®¼à¯¢à¯¡à¯§à¯¥à¯¢à¯Ÿ  < 
2.5%) 0.5 90 86.7 
95 79.0 
1.0 90 60.5 
95 61.0 
1.5 90 61.1 
95 48.2 
Superiority ( ÝŒà¯à¯˜à¯¦à¯§ <5%) 
 0.5 90 95.6 
95 92.9 
1.0 90 85.9 
95 81.1 
1.5 90 73.3 
95 67.8 
Superiority ( ÝŒà®¼à¯¢à¯¡à¯§à¯¥à¯¢à¯Ÿ <5%) 
 0.[ADDRESS_385222] a 
difference of 0.5% between lenses. Therefore, a pproximately 33 subjects will be enrolled to 
account for screen failures/dropouts with a mi nimum target of 30 subj ects to complete.  
CR-6530, v 1.0  
 
Page 46 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 14.3. Analysis Populations 
Safety Population: All subjects who are administered any test ar ticle excluding subjects who drop out prior to 
administering any test article. At least one observation should be recorded.  Per-Protocol Population:  All subjects who successfully comp lete all visits and do not substantially deviate from the 
protocol as determined by [CONTACT_126125]. 
Justification for the exclusion of subjects with  protocol deviations from the per-protocol 
population set will be docume nted in a memo to file. 
 
Intent-to-Treat (ITT) Population: All randomized subjects regardless of actual treatment and subsequent withdrawal from the 
study or deviation from the pr otocol. At least one obser vation should be recorded. 
14.4. Level of Statistical Significance 
Not applicable. No statistical testing will be performed. 
14.5. Primary Analysis  
All primary endpoints will be de scriptively summarized by [CONTACT_312804] (baseline, 
fitting).   
14.6. Secondary Analysis  
Not applicable.  
14.7. Other Exploratory Analysis 
All exploratory endpoints will be descriptively su mmarized by [CONTACT_312804] (baseline, 
fitting).   
14.8. Interim Analysis  
Not applicable.  
14.9. Procedure for Handling Missing Data and Drop-Outs 
Missing or spurious values will not be imputed. The count of missing values will be included in the summary tabl es and listings.  
14.10. Procedure for Reporting Deviations from Statistical Plan 
The analysis will be conducted according to th at specified in above sections. There are no 
known reasons for which it is planned to deviate from these analysis methods. If for any reason 
a change is made, the change will be documented in the study report along with a justification 
for the change. 
CR-6530, v 1.0  
 
Page 47 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 15. DATA HANDLING AND RECORD KEEPI[INVESTIGATOR_1645]/ARCHIVING 
15.1. Electronic Case Report Form/Data Collection 
The data for this study will be captured on electronic case report fo rms (eCRFs) using the 
BioClinica EDC system. An authorized data orig inator will enter study data into the eCRFs 
using the EDC system. Data collected on equipm ent that is not captured in EDC will be 
formatted to the specification of the JJVC data base manager and sent to JJVC for analysis.  
 No external data sources w ill be included in this study.  
 The clinical data will be recorded on dedicate d eCRFs specifically designed to match the study 
procedures for each visit. Only specifically de legated staff can enter data on a CRF.  Once 
completed, the eCRFs will be reviewed for accuracy and completeness and signed by [CONTACT_3786]. The sponsor or sponsorâ€™s representa tives will be authorized to gain access to the 
subject recordation for the purposes of  monitoring and auditing the study.  
 Edit checks, electronic queries, an d audit trails are built into the system to ensure accurate and 
complete data collection. Data will be transmitt ed from the clinical site to a secure central 
database as forms are completed or updated,  ensuring information accuracy, security, and 
confidentiality. After the final database lock, th e Investigator will be provided with Individual 
Patient Profiles (IPP) including the full audit trai l on electronic media in PDF format for all of 
the study data. The IPP must be retained in the st udy files as a certified copy of the source data 
for the study.   The content and structure of the eCRFs are compliant with ISO14155:2020.
[ADDRESS_385223] should be available for the following:  
x subject identification 
x eligibility 
x study identification 
x study discussion 
x provision of and date of informed consent 
x visit dates 
x results of safety and efficacy para meters as required by [CONTACT_760] 
x a record of all adverse events 
x follow-up of adverse events 
x medical history and concomitant medication 
x test article receipt/dispensing/return records 
x date of study completion 
x reason for early discontinuation of test article or withdrawal from the study, if 
applicable  
CR-6530, v 1.0  
 
Page 48 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 The subject record is the eCRF or an external record. The aut hor of an entry in the subject 
record must be identifiable. Th e first point of entry is consid ered to be the source record. 
 
Adverse event notes must be reviewed  and initialed by [CONTACT_737]. 
 
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov by [CONTACT_1034]. 
16. DATA MANAGEMENT 
16.1. Access to Source Data/Document 
The Investigator/Institution will permit trial-related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_312805]/documents. Should the 
clinical site be contact[CONTACT_35527]/IRB or regulatory authority, JJVC must be 
contact[CONTACT_19592] [ADDRESS_385224] and therefore may disclose it as required 
to other clinical investigators and to regulatory agencies. In order to allow the use of the 
information derived from this clinical study, th e Investigator understands that he/she has an 
obligation to provide complete test results an d all data developed du ring this study to the 
Sponsor. 
16.3. Data Quality Assurance 
Steps will be taken to ensure the accuracy and reliability of data, in cluding the selection of 
qualified investigators a nd appropriate clinical s ites and review of prot ocol procedures with 
the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-
Investigators and clinical site personnel are familiar with the pr otocol and all study-specific 
procedures and have appropriate knowledge of the study article. 
 Training on case report form comp letion will be provide d to clinical site personnel before the 
start of the study. The Sponsor will review case report forms for accuracy and completeness 
remotely during the con duct of the study, during monitoring visits, and after transmission to 
data management. Any data discre pancies will be resolved with the Investigator  or designee, 
as appropriate.  Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during the study and to access compliance with a pplicable regulations pertaining to the conduct 
CR-6530, v 1.0  
 
Page 49 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 of clinical trials. The clinical sites will provide direct access to study-related source 
data/documents and reports for the purpose of monitoring and auditing by [CONTACT_35529]. 
16.4. Data Monitoring Committee (DMC) 
Not applicable.  
17. CLINICAL MONITORING 
The study monitors will maintain  close contact [CONTACT_312806]â€™s designated clini cal site personnel. The monitorâ€™ s responsibilities will include: 
x Ensuring that the investigation is being conducted according to  the protocol, any 
subsequent versions, and regulato ry requirements are maintained. 
x Ensuring the rights and wellbeing of subjects are protected. 
x Ensuring adequate resources, including faci lities, laboratories, equipment, and 
qualified clinical site personnel. 
x Ensuring that protocol deviat ions are documented with co rrective acti on plans, as 
applicable. 
x Ensuring that the clinical site has sufficient test articles and supplies. 
x Clarifying questions regarding the study. 
x Resolving study issues or problems that may arise. 
x Reviewing of study records and source docum entation verification in accordance with 
the monitoring plan. 
18. ETHICAL AND REGULATORY ASPECTS 
18.1. Study-Specific Design Considerations 
Potential subjects will be fully informed of th e risks and requirements of the study, and during 
the study, subjects will be given a ny new information that may affect their decision to continue 
participation. Subjects will be told that their c onsent to participate in the study is voluntary and 
may be withdrawn at any time with no reason give n and without penalty or loss of benefits to 
which they would otherwise be entitled. Subjects will only be enrolled if  the subject is fully 
able to understand the risks, benefits, and potential adverse events of the study and provide 
their consent voluntarily.  
18.2. Investigator Responsibility 
The Principal Investigator [INVESTIGATOR_312777], the in vestigational plan, according to ISO [ZIP_CODE]:2020,
[ADDRESS_385225] provides public assurance that 
the rights, safety, and well-being of study subjects are protected, c onsistent with the principles 
CR-6530, v 1.0  
 
Page 50 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 of the Declaration of Helsinki 64th WMA General Assembly [ADDRESS_385226] (IEC/IRB) 
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (where applicable): 
x Final protocol. 
x Sponsor-approved informed consent form (a nd any other written materials to be 
provided to the subjects) 
x Investigatorâ€™s Brochure (or equivalent information). 
x Sponsor-approved subject recruitment materials. 
x Information on compensation for study-related injuries or payment to subjects for 
participation in the study. 
x Investigatorâ€™s curriculum vit ae, clinical licenses, or equi valent information (unless not 
required, as documen ted by [CONTACT_8134]/IRB). 
x Information regarding funding, name [CONTACT_19618], institutional affiliations, other 
potential conflicts of interest , and incentives for subjects. 
x Any other documents that the IEC/IRB requests to fulfill its obligation. 
 This study will be undertaken only after IEC/IRB has given full approval of the final protocol, 
the informed consent form, applicable recr uiting materials, and subject compensation 
programs, and the Sponsor has rece ived a copy of this approval. This approval letter must be 
dated and must clearly identify  the documents being approved. 
 During the study, the Investigator (or Sponsor  when applicable) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate: 
x Protocol revisions 
x Revision(s) to informed consent form and a ny other written materials to be provided to 
subjects 
x If applicable, new or revise d subject recruitment materi als approved by [CONTACT_1034] 
x Revisions to compensation fo r study-related injuries or  payment to subjects for 
participation in the study 
x Investigatorâ€™s Br ochure revisions  
x Summaries of the status of the study (at le ast annually or at intervals stipulated in 
guidelines of the IEC/IRB) 
x Reports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRBâ€™s requirements 
x New information that may adversely
  affect th e safety of the subjec ts or the conduct of 
the study 
x Major protocol deviations as required by [CONTACT_6179]/IRB 
x Report of deaths of subjects  under the Investigator's care 
x Notification if a new Investigator is res ponsible for the study at the clinical site 
CR-6530, v 1.0  
 
Page 51 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 x Any other requirements of the IEC/IRB 
 For protocol revisions that incr ease subject risk, the revisions a nd applicable informed consent 
form revisions must be submitted promptly to  the IEC/IRB for review and approval before 
implementation of the change(s).  At least once a year, the IEC/I RB will review and reapprove th is clinical study. This request 
should be documented in writing.  At the end of the study, the I nvestigator (or Sponsor where re quired) will notify the IEC/IRB 
about the study completion. Document ation of this notification must be retain ed at the clinical 
site and a copy provided to the CRO or Sponsor as applicable. 
18.4. Informed Consent 
Each subject or their representative must give written consent according to local requirements 
after the nature of the study has been fully expl ained. The consent form must be signed before 
performance of any study -related activity. The consent form that is used must be approved by 
[CONTACT_19597]/IRB. The informed consent is in accordance with 
principles that originated in the Declaration of Helsinki,
 2 and ISO [ZIP_CODE]:[ADDRESS_385227] will be given sufficient time to read  the informed consent form and the opportunity 
to ask questions. After this ex planation and before entry into  the study, consent should be 
appropriately recorded by [CONTACT_312807] t's dated signature. Af ter having obtained the 
consent, a copy of the info rmed consent form must be given to the subject. 
18.5. Privacy of Personal Data 
The collection, processing and disclosure of pers onal data and medical information related to 
the Study Subject, and personal data related to Pr incipal Investigator and any clinical site 
personnel (e.g., name, clinic addr ess and phone number, curriculum vitae) is subject to 
compliance with the Health Information Portability a nd Accountability Act (HIPAA)
[ADDRESS_385228] these data, to maintain the confidentiality of the 
personâ€™s related health and medical informatio n, to properly inform the concerned persons 
about the collection and processi ng of their personal data, to grant them reasonable access to 
their personal data and to prev ent access by [CONTACT_35532]. 
 
CR-6530, v 1.0  
 
Page 52 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 All information obtained during the course of the investigation will be regarded as confidential. 
All personal data gathered in this trial will be  treated in strictest c onfidence by [CONTACT_4718], 
monitors, Sponsorâ€™s personnel and IEC/IRB. No data will be disclosed to any third party 
without the express permission of the subject concerned, with the exception of Sponsor 
personnel (monitor, auditor), IEC/IRB and regulat ory organizations in the context of their 
investigation related activities that, as part of  the investigation will have access to the CRFs 
and subject records.  The collection and processing of personal data from subjects enrolled in this study will be limited to those data that are necessary to invest igate the efficacy, safety, quality, and utility of 
the investigationa l product(s) used in this study. 
 These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data pr ivacy protection laws and regulations. 
The Sponsor ensures that th e personal data will be: 
x processed fairly and lawfully. 
x collected for specified, explicit,  and legitimate purposes and not further processed in a 
way incompatible with these purposes. 
x adequate, relevant, and not excessive in relation to said purposes. 
x accurate and, where necessary, kept current. 
 Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Such consent sh ould also address the transfer of the data to 
other entities and to other countries.  
The subject has the right to reque st through the Investigator acce ss to his personal data and the 
right to request rectification of any data that  are not correct or complete. Reasonable steps 
should be taken to respond to such a request, taki ng into consideration the nature of the request, 
the conditions of the study, and the applicable laws and regulations. 
 
Appropriate technical and or ganizational measures to protect personal data against 
unauthorized disclosures or access,  accidental or unlawful destruc tion, or accidental loss or 
alteration must be put in place. Sponsor pers onnel whose responsibilities require access to 
personal data agree to keep the iden tity of study subjects confidential. 
19. STUDY RECORD RETENTION 
In compliance with the ISO [ZIP_CODE]:2020,
1 guideline, the Investigator/Institution will maintain 
all CRFs and all subject records that support the data collected from each subject, as well as 
all study documents as specified in ISO [ZIP_CODE]:2020,1 and all study documents as specified by 
[CONTACT_8146](s). The Investigator/Institution will take measures to prevent accidental or premature destruction of these documents.  
CR-6530, v 1.0  
 
Page 53 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 Essential documents must be retained until at le ast two (2) years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated marketing applications in an IC H region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical developm ent of the investigational product. These 
documents will be retain ed for a longer period if requir ed by [CONTACT_35533]. It is the responsibility of the Sponsor to inform the 
Investigator/Institution as to when these documents no longer need to be retained. 
 If the responsible Investigator retires, relocat es, or for other reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custody must be transferred to a person who will accept the responsibility. The Sponsor must be no tified in writing of the name [CONTACT_19619]. Under no circ umstance shall the Investigator relocate or dispose of any 
study documents before having obtained written approval from the Sponsor. 
 If it becomes necessary for the Sponsor or the appropr iate regulatory authority to review any 
documentation relating to this st udy, the Investigator must permit  access to such reports.  
If the Investigator has a question regarding rete ntion of study records, he/she should contact 
[CONTACT_19599].  
20. FINANCIAL CONSIDERATIONS 
Remuneration for study services and expenses will be set forth in detail in the Clin ical Research 
Agreement. The Research Agreement will be si gned by [CONTACT_079] [INVESTIGATOR_1238] a JJVC 
management representative prior to study initiation. 
 JJVC reserves the right to withhol d remuneration for costs associat ed with protocol violations 
such as: 
x Continuing an ineligible  subject in the study. 
x Scheduling a study visit outside the subjectâ€™s acceptable visit range. 
 
JJVC reserves the right to withhold final remuneration until a ll study related activities have 
been completed, such as: 
x Query resolution. 
x Case Report Form signature. 
x Completion of any fo llow-up action items. 
21. PUBLICATION 
There is no plan to publish the outcome of this investigation. 
22. REFERENCES 
1. ISO [ZIP_CODE]:2020: Clinical Investigation of Medical Devices for Human Subjects â€” 
Good Clinical Practice. Available at: https://www.iso.org/standard/[ZIP_CODE].html 
CR-6530, v 1.0  
 
Page 54 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 2. Declaration of Helsinki - Et hical principles for Medica l Research Involving Human 
Subjects. Available at: https://www.wma.net/policies-post/w ma-declaration-of-
helsinki-ethical-principles-for-medical-research-involving-human-subjects/  
3. [LOCATION_002] (US) Code of Federa l Regulations (CFR). Available at: 
https://www.gpo.gov/fdsys/browse/collecti onCfr.action?collectionCode=CFR  
4. Health Information Portab ility and Accountability Ac t (HIPAA). Available at: 
https://www.hhs.gov/hipaa/for-professionals/p rivacy/index.html  
5. SAS Institute Inc: SASÂ® 9.4 Statements: Reference TEC, NC: SAS Institute Inc; 2014. 
6. Diniz CAR, Tutia MH, Leite JG. Bayesian analysis of a correlated binomial model. Brazilian Journal of Probabil ity and Statistics. 2010;24(1). 
7. Chen Z, McGee M. A Bayesian Appro ach to Zero-Numerat or Problems Using 
Hierarchical Models. Journal of Data Science. 2021;6(2):261-268. 
  
  
CR-6530, v 1.0  
 
Page 55 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 APPENDIX A: PATIENT REPORTED OU TCOMES (STUDY QUESTIONNAIRES) 
PROTOCOL CR-6530 PRO SPECIFICATION  
  
CR-6530, v 1.0  
 
Page 56 of 137JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
CR-6530, v 1.0  
 
Page 57 of 137JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2
CR-6530, v 1.0  
 
Page 58 of 137JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
CR-6530, v 1.0  
 
Page 59 of 137JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
CR-6530, v 1.0  
 
Page 60 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 APPENDIX B: PATIENT IN STRUCTION GUIDE   
A Patient Instruction Guide (PIG) will be provided separately. 
CR-6530, v 1.0  
 
Page 61 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) 
ACUVUE OASYSÂ® Brand Contact [CONTACT_32993] 1-Day with HydraLuxeTM Technology for 
ASTIGMATISM 
  
CR-6530, v 1.0  
 
Page 62 of 137JJVC CONFIDENTIAL
DESCRIPTION
ACUVUE OASYSÂ® Brand Contact [CONTACT_32993] 1-Day and ACUVUE OASYSÂ® 
Brand Contact [CONTACT_32993] 1-Day for ASTIGMATISM are soft (hydrophilic) 
contact [CONTACT_35538]â„¢ Technology. They are available as spherical or toric lenses respectively. 
These lenses are made of a silicone hydrogel material containing an internal 
wetting agent, visibility tint, and UV absorbing monomer and are tinted blue using Reactive Blue Dye #4 to make the lenses more visible for handling.
A benzotriazole UV absorbing monomer is used to block UV radiation. The 
transmittance characteristics for these lenses are less than 1% in the UVB range of 280 nm to 315 nm and less than 10% in the UVA range of 316 nm to 380 nm 
for the entire power range.
Lens Properties:
The physical/optical properties of the lens are:
â€¢ Speciï¬  c Gravity (calculated): 0.98 - 1.12
â€¢ Refractive Index: 1.42
â€¢ Light Transmission: 85% minimum
â€¢ Surface Character: Hydrophilic
â€¢ Water Content: 38%
â€¢ Oxygen Permeability:
VALUE METHOD
122 x 10-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35Â°CFatt (boundary corrected, non-
edge corrected)
103 x 10-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35Â°CFatt (boundary corrected, edge corrected)
Lens Parameters:
â€¢ Diameter Range: 12.0 mm to 15.0 mm
â€¢ Center Thickness: varies with power
â€¢ Base Curve Range: 7.85 mm to 10.00 mm
â€¢ Spherical Power Range: -20.00D to [PHONE_565]D
â€¢ Cylinder Power Range: -0.25D to -10.00D
â€¢ Axis Range: 2.5Â° to 180Â°
CR-6530, v 1.0  
 
Page 65 of 137JJVC CONFIDENTIAL
AVAILABLE LENS PARAMETERS
ACUVUE OASYSÂ® Brand 1-Day with HydraLuxeâ„¢ Technology are 
hemispherical shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.085 mm to 0.221 mm (varies with power)
Base Curve: 8.5 mm, 9.0 mm
Powers: -0.50D to -6.00D (in 0.25D increments)
-6.50D to -12.00D (in 0.50D increments)+0.50D to +6.00D (in 0.25D increments)+6.50D to +8.00D (in 0.50D increments)
ACUVUE OASYSÂ® Brand 1-Day with HydraLuxeâ„¢ Technology for 
ASTIGMATISM  are hemitoric shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.075 mm to 0.172 mm (varies with power)
Base Curve: 8.5 mm
Powers: +0.00D to -6.00D (in 0.25D increments)
Cylinders: -0.75D, -1.25D, -1.75D, -2.25D*Axis: 10Â° to 180Â° in 10Â° increments
*-2.25D cylinder is availble in 10Â°, 20Â°, 70Â°, 80Â°, 90Â°, 100Â°, 110Â°, 
160Â°, 170Â°, 180Â° axes only.
+0.25D to +4.00D (in 0.25D increments)
-6.50D to -9.00D (in 0.50D increments)Cylinders: -0.75D, -1.25D, -1.75DAxis: 10Â°, 20Â°, 70Â°, 80Â°, 90Â°, 100Â°, 110Â°, 160Â°, 
170Â°, 180Â°
CR-6530, v 1.0  
 
Page 66 of 137JJVC CONFIDENTIAL
TRANSMITTANCE CURVES
ACUVUE OASYSÂ® 1-Day with HydraLuxeâ„¢ Technology  (senoï¬  lcon A) 
Visibility Tinted with UV Blocker vs. 24 yr. old human cornea and 25 yr. old 
human crystalline lens. 
â€¦â€¦. ACUVUE OASYSÂ®  
1-Day with HydraLuxeâ„¢ Technology (senoï¬  lcon A)*
_____ 24 YR. OLD HUMAN CORNEA
1
- - - - - 25 YR. OLD HUMAN CRYSTALLINE LENS
2
* The data was obtained from measurements taken through the central 3-[ADDRESS_385229] marketed lens (-9.00D lens, 0.075 mm center thickness).
1Lerman, S., Radiant Energy and the Eye, MacMillan, [LOCATION_001], 1980, p. 58, ï¬  gure 2-21
2Waxler, M., Hitchins, V.M., Optical Radiation and Visual Health, CRC Press, Boca Raton, [LOCATION_012], 
1986, p. 19, ï¬  gure 5 
WARNING: UV absorbing contact [CONTACT_35539], such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. The patient should continue to use UV absorbing eyewear as directed.
ACTIONS
In its hydrated state, the contact [CONTACT_13293], when placed on the cornea, acts as a refracting medium to focus light rays onto the retina.
The transmittance characteristics for these lenses are less than 1% in the 
UVB range of 280 nm to 315 nm and less than 10% in the UVA range of 316 nm to 380 nm for the entire power range.
CR-6530, v 1.0  
 
Page 67 of 137JJVC CONFIDENTIAL
NOTE:  Long-term exposure to UV radiation is one of the risk 
factors associated with cataracts.  Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities).  UV-Blocking contact [CONTACT_35540]. However, clinical studies have not been done to demonstrate that wearing UV-Blocking contact [CONTACT_35541][INVESTIGATOR_35457]. The Eye Care Professional should be consulted for more information.
INDICATIONS (USES)
ACUVUE OASYSÂ® Brand Contact [CONTACT_32993] 1-Day with HydraLuxeâ„¢ 
Technology are indicated for daily disposable wear for the optical correction of refractive ametropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes who may have 1.00D or less of astigmatism.
ACUVUE OASYSÂ® Brand Contact [CONTACT_32993] 1-Day with HydraLuxeâ„¢ Tech-
nology for ASTIGMATISM are indicated for daily disposable wear for the 
optical correction of refractive ametropia (myopia and hyperopia) in phakic 
or aphakic persons with non-diseased eyes who may have 0.50D to 3.00D of astigmatism.
These lenses contain a UV Blocker to help protect against transmission of 
harmful UV radiation to the cornea and into the eye.
CONTRAINDICATIONS (REASONS NOT TO USE) 
DO NOT USE these contact [CONTACT_35542]:
â€¢ Acute or subacute inï¬‚  ammation or infection of the anterior chamber 
of the eye.
â€¢ Any eye disease, injury or abnormality that affects the cornea, 
conjunctiva, or eyelids.
â€¢ Severe insufï¬  ciency of lacrimal secretion (dry eye).
CR-6530, v 1.0  
 
Page 68 of 137JJVC CONFIDENTIAL
â€¢ Corneal hypoesthesia (reduced corneal sensitivity).
â€¢ Any systemic disease that may affect the eye or be exaggerated by 
[CONTACT_35543].
â€¢ Allergic reactions of ocular surfaces or adnexa that may be induced 
or exaggerated by [CONTACT_71186].
â€¢ Ocular irritation due to allergic reactions which may be caused by 
[CONTACT_35545] (i.e., rewetting drops) that contain chemicals or preservatives (such as mercury, Thimerosal, etc.) to which some people may develop an allergic response.
â€¢ Any active corneal infection (bacterial, fungal, protozoal, or viral).
â€¢ If eyes become red or irritated.
WARNINGS
Patients should be advised of the following warnings pertaining to 
contact [CONTACT_13279]:
EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN DEVELOP 
RAPI[INVESTIGATOR_35458]; IF THE PATIENT EXPE-RIENCES:
â€¢ Eye Discomfort,
â€¢ Excessive Tearing,â€¢ Vision Changes,â€¢ Loss of Vision,â€¢ Eye Redness,â€¢ Or Other Eye Problems, 
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY RE-
MOVE THE LENSES AND PROMPTLY CONTACT [CONTACT_35546].
â€¢ When prescribed for daily wear, patients should be instructed not 
to wear lenses while sleepi[INVESTIGATOR_007]. Clinical studies have shown that 
the risk of serious adverse reactions is increased when lenses are worn overnight, and that the risk of ulcerative keratitis is greater for 
CR-6530, v 1.[ADDRESS_385230] lens users than for daily wear users.3
â€¢ Studies have shown that contact [CONTACT_126129] a higher incidence of adverse reactions than nonsmokers.
â€¢ Problems with contact [CONTACT_126130]. Patients should be cautioned that proper 
use and care of contact [CONTACT_126131].
â€¢ The overall risk of ulcerative keratitis may be reduced by [CONTACT_126132].
3 New England Journal of Medicine, September 21, 1989; 321 (12), pp. 773-783
Speciï¬  c Instructions for Use and Warnings:
â€¢ Water Activity
Instructions for Use
Do not expose contact [CONTACT_35551].WARNING:
Water can harbor microorganisms that can lead to severe infection, vision loss or blindness. If lenses have been submersed in water when participating in water sports or swimming in pools, hot tubs, lakes, or oceans, the patient should be instructed to discard them and replace them with a new pair. The Eye Care Professional should be consulted for recommendations regarding wearing lenses during any activity involving water.
PRECAUTIONS
Special Precautions for Eye Care Professionals:
â€¢ Due to the small number of patients enrolled in clinical investiga-
tion of lenses, all refractive powers, design conï¬  gurations, or lens parameters available in the lens material are not evaluated in signif-icant numbers. Consequently, when selecting an appropriate lens design and parameters, the Eye Care Professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, wettability, central and peripheral thickness, and optic zone diameter.
CR-6530, v 1.0  
 
Page 70 of 137JJVC CONFIDENTIAL
â€¢ The potential impact of these factors on the patientâ€™s ocular health 
should be carefully weighed against the patientâ€™s need for refractive 
correction; therefore, the continuing ocular health of the patient and lens performance on the eye should be carefully monitored by [CONTACT_71187].
â€¢ Patients who wear these lenses to correct presby[CONTACT_35553]-
vision may not achieve the best corrected visual acuity for either far or near vision. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
â€¢ Fluorescein, a yellow dye, should not be used while the lenses are 
on the eyes. The lenses absorb this dye and become discolored. Whenever ï¬‚  uorescein is used in eyes, the eyes should be ï¬‚  ushed with a sterile saline solution that is recommended for in-eye use.
â€¢ Eye Care Professionals should instruct the patient to remove the 
lenses immediately if the eyes become red or irritated. 
Eye Care Professionals should carefully instruct patients about the following care regimen and safety precautions.
Handling Precautions:
â€¢ Before leaving the Eye Care Professionalâ€™s ofï¬  ce, the patient should 
be able to promptly remove the lenses or should have someone 
else available who can remove the lenses for him or her. 
â€¢ DO NOT use if the sterile blister package is opened or damaged. 
â€¢ Always wash and rinse hands before handling lenses. Do not get 
cosmetics, lotions, soaps, creams, deodorants, or sprays in the 
eyes or on the lenses. It is best to put on lenses before putting on makeup. Water-based cosmetics are less likely to damage lenses than oil-based products. 
â€¢ DO NOT touch contact [CONTACT_35554] ï¬  ngers or hands if the 
hands are not free of foreign materials, as microscopic scratches of the lenses may occur, causing distorted vision and/or injury to the eye.
â€¢ Carefully follow the handling, insertion, removal, and wearing 
instructions in the â€œPatient Instruction Guideâ€ for the prescribed 
CR-6530, v 1.0  
 
Page 71 of 137JJVC CONFIDENTIAL
wearing schedule and those prescribed by [CONTACT_35555].
â€¢ Always handle lenses carefully and avoid droppi[INVESTIGATOR_35459].
â€¢ Never use tweezers or other tools to remove lenses from the lens 
container unless speciï¬  cally indicated for that use. Slide the lens up 
the side of the bowl until it is free of the container. 
â€¢ Do not touch the lens with ï¬  ngernails. 
Lens Wearing Precautions:
â€¢ If the lens sticks (stops moving) on the eye, follow the recom-
mended directions in â€œCare for a Sticking (Non-Moving) Lens." The lens should move freely on the eye for the continued health of the eye. If non-movement of the lens continues, the patient should be instructed to immediately consult his or her Eye Care Professional.
â€¢ Never wear lenses beyond the period recommended by [CONTACT_71188].
â€¢ The patient should be advised to never allow anyone else to wear 
their lenses. They have been prescribed to ï¬  t their eyes and to correct their vision to the degree necessary. Sharing lenses greatly increases the chance of eye infections.
â€¢ If aerosol products, such as hair spray, are used while wearing 
lenses, exercise caution and keep eyes closed until the spray has settled.
â€¢ Avoid all harmful or irritating vapors and fumes while wearing 
lenses. 
â€¢ Always discard lenses worn as prescribed by [CONTACT_35555]. 
Lens Care Precautions:  
â€¢ The patient should be informed that no cleaning or disinfection is 
needed when lenses are worn for daily disposable wear.  Patients should always dispose of lenses when removed and have spare lenses or spectacles available.
CR-6530, v 1.0  
 
Page 72 of 137JJVC CONFIDENTIAL
Other Topi[INVESTIGATOR_35460]:
â€¢ Always contact [CONTACT_35558]-
cine in the eyes. 
â€¢ Certain medications, such as antihistamines, decongestants, 
diuretics, muscle relaxants, tranquilizers, and those for motion 
sickness may cause dryness of the eye, increased lens awareness, or blurred vision. Should such conditions exist, proper remedial measures should be prescribed. Depending on the severity, this could include the use of lubricating drops that are indicated for use with soft contact [CONTACT_71189]. 
â€¢ Oral contraceptive users could develop visual changes or changes 
in lens tolerance when using contact [CONTACT_13276]. Patients should be cautioned accordingly. 
â€¢ As with any contact [CONTACT_13293], follow-up visits are necessary to assure 
the continuing health of the patientâ€™s eyes. The patient should be instructed as to a recommended follow-up schedule. 
Who Should Know That the Patient is Wearing Contact [CONTACT_32993]?
â€¢ Patients should inform all doctors (Health Care Professionals) about 
being a contact [CONTACT_35560]. 
â€¢ Patients should always inform their employer of being a contact 
[CONTACT_35560]. Some jobs may require use of eye protection equip-ment or may require that the patient not wear contact [CONTACT_13276]. 
ADVERSE REACTIONS
The patient should be informed that the following problems may occur when wearing contact [CONTACT_13276]:
â€¢ The eye may burn, sting, and/or itch.
â€¢ There may be less comfort than when the lens was ï¬  rst placed on 
the eye.
â€¢ There may be a feeling of something in the eye (foreign body, 
scratched area).
â€¢ There may be the potential for some temporary impairment due to 
CR-6530, v 1.0  
 
Page 73 of 137JJVC CONFIDENTIAL
peripheral inï¬  ltrates, peripheral corneal ulcers, or corneal erosion. 
There may be the potential for other physiological observations, such as local or generalized edema, corneal neovascularization, corneal staining, injection, tarsal abnormalities, iritis, and conjuncti-vitis; some of which are clinically acceptable in low amounts.
â€¢ There may be excessive watering, unusual eye secretions, or 
redness of the eye.
â€¢ Poor visual acuity, blurred vision, rainbows, or halos around 
objects, photophobia, or dry eyes may also occur if the lenses are worn continuously or for too long a time.
The patient should be instructed to conduct a simple 3-part self-examina-tion at least once a day. They should ask themselves:
â€¢ How do the lenses feel on my eyes?
â€¢ How do my eyes look?â€¢ Have I noticed a change in my vision? 
If the patient reports any problems, he or she should be instructed to 
IMMEDIATELY REMOVE THE LENS. If the problem or discomfort stops, the patient should discard the lens and place a new fresh lens on the eye.
If after inserting the new lens, the problem continues, the patient should be 
directed to IMMEDIATELY REMOVE THE LENS AND CONTACT [CONTACT_35561].
The patient should be instructed NOT to use a new lens as self-treatment 
for the problem.
The patient should be advised that when any of the above symptoms oc-
cur, a serious condition such as infection, corneal ulcer, neovascularization, or iritis may be present. He or she should be instructed to seek immediate professional identiï¬  cation of the problem and prompt treatment to avoid serious eye damage.
CR-6530, v 1.0  
 
Page 74 of 137JJVC CONFIDENTIAL
GENERAL FITTING GUIDELINES
A. Patient Selection
Patients selected to wear these lenses should be chosen based on: 
â€¢ Motivation to wear lenses 
â€¢ Ability to follow instructions regarding lens wear care
â€¢ General health 
â€¢ Ability to adequately handle and care for the lenses 
â€¢ Ability to understand the risk and beneï¬  ts of lens wear
Patients who do not meet the above criteria should not be provided with contact [CONTACT_13276]. 
B. Pre-ï¬  tting Examination
Initial evaluation of the patient should begin with a thorough case history 
to determine if there are any contraindications to contact [CONTACT_13279]. During 
the case history, the patientâ€™s visual needs and expectations should be 
determined as well as an assessment of their overall ocular, physical, and 
mental health. 
Preceding the initial selection of trial contact [CONTACT_13276], a comprehensive 
ocular evaluation should be performed that includes, but is not limited to, 
the measurement of distance and near visual acuity, distance and near 
refractive prescription (including determining the preferred reading distance 
for presby[CONTACT_35562]), keratometry, and biomicroscopic evaluation. 
Based on this evaluation, if it is determined that the patient is eligible to 
wear these lenses, the Eye Care Professional should proceed to the lens 
ï¬  tting instructions as outlined below. 
C. Initial Power Determination
A spectacle refraction should be performed to establish the patientâ€™s 
baseline refractive status and to guide in the selection of the appropriate 
lens power. Remember to compensate for vertex distance if the refraction 
is greater than Â±4.00D.
D. Base Curve Selection (Trial Lens Fitting)
The following trial lenses should be selected for patients regardless of kera-
tometry readings. However, corneal curvature measurements should be 
performed to establish the patientâ€™s baseline ocular status. 
CR-6530, v 1.0  
 
Page 75 of 137JJVC CONFIDENTIAL
â€¢ ACUVUE OASYSÂ® 1-Day: 8.5 mm/14.3 mm
â€¢ ACUVUE OASYSÂ® 1-Day for ASTIGMATISM: 8.5 mm/14.3 mm
The trial lens should be placed on each of the patient's eyes and evaluated 
after the patient has adjusted to the lenses.  
1. Criteria of a Properly Fit Lens 
A properly ï¬  t lens will center and completely cover the cornea (i.e., no limbal exposure), have sufï¬  cient movement to provide tear exchange under the contact [CONTACT_35563], and be comfortable. The lens should move freely when manipulated digitally with the lower lid, and then return to its properly centered position when released.
2. Criteria of a Flat Fitting Lens 
A ï¬‚  at ï¬  tting lens may exhibit one or more of the following characteris-tics: decentration, incomplete corneal coverage (i.e., limbal exposure), excessive movement with the blink, and/or edge standoff. If the lens is judged to be ï¬‚  at ï¬  tting, it should not be dispensed to the patient.
3. Criteria of a Steep Fitting Lens 
A steep ï¬  tting lens may exhibit one or more of the following charac-teristics: insufï¬  cient movement with the blink, conjunctival indentation, and resistance when pushing the lens up digitally with the lower lid. If the lens is judged to be steep ï¬  tting, it should not be dispensed to the patient.
If the initial trial base curve is judged to be ï¬‚  at or steep ï¬  tting, the alternate base curve, if available, should be trial ï¬  t and evaluated after the patient has adjusted to the lens. The lens should move freely when manipulated digitally with the lower lid, and then return to a properly centered position when released. If resistance is encountered when pushing the lens up, the lens is ï¬  tting tightly and should not be dispensed to the patient.
E. Final Lens Power (Spherical)
A spherical over-refraction should be performed to determine the ï¬  nal lens power after the lens ï¬  t is judged acceptable. The spherical over-refraction should be combined with the trial lens power to determine the ï¬  nal lens prescription. The patient should experience good visual acuity with the correct lens power unless there is excessive residual astigmatism.
CR-6530, v 1.0  
 
Page 76 of 137JJVC CONFIDENTIAL
Example 1
Diagnostic lens: -2.00DSpherical over-refraction: -0.25D
Final lens power: -2.25D
Example 2
Diagnostic lens: -2.00DSpherical over-refraction: +0.25D
Final lens power: -1.75D
If vision is acceptable, perform a slit lamp examination to assess adequate 
ï¬  t (centration and movement). If the ï¬  t is acceptable, dispense the lenses and instruct the patient to return in one week for reassessment (see dispensing and follow up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copi[INVESTIGATOR_35461].acuvue.com.
TORIC FITTING GUIDELINES
Although most aspects of the ï¬  tting procedure are identical for all types 
of soft contact [CONTACT_13276], including toric lenses, there are some additional steps and/or rules to follow to assure the proper ï¬  t of toric lenses.
The only new steps you must follow in prescribing ACUVUE
 OASYSÂ® 
1-Day for ASTIGMATISM are that you must determine the stability, 
repeatability, and drift angle of the lens axis so that you can prescribe the correct lens axis for the patient.
A. How to Determine Lens Cylinder and Axis Orientation 
1. Locate the Orientation Marks
To help determine the proper orientation of the toric lens, youâ€™ll 
ï¬  nd two primary marks approximately 1 mm from the lens edge representing the vertical position on opposite ends of the lens at 6 and 12 oâ€™clock (Fig. 1). Because of the lensâ€™ ballasting system, either mark can represent the vertical position â€“ there is no â€œtopâ€ and â€œbottomâ€ as in a prism-ballasted lens. You donâ€™t need to view both marks to assess orientation; simply look for the 6 oâ€™clock mark as you would with a prism-ballasted lens.
CR-6530, v 1.0  
 
Page 77 of 137JJVC CONFIDENTIAL
Figure 1
Youâ€™ll need a slit lamp biomicroscope with a 1 to 2 mm 
parallelepi[INVESTIGATOR_35462] ï¬  tted to the eye. There are a number of techniques you can use to improve the visibility of the 6 oâ€™clock mark. Using a parallelepi[INVESTIGATOR_35463]ï¬  cation (10x or 15x), slowly pan down the lens, looking just below the direct illumination at the retroilluminated area. Backlighting the mark this way should make it more visible. Sometimes manipulating the lower lid may be necessary to uncover the mark.
2. Observe Lens Rotation and Stability
Observe the position and stability of the â€œbottomâ€ mark. It usually stabilizes at the 6 oâ€™clock position. If it does, calculation of the lens power will be straightforward. The 6 oâ€™clock position is not a â€œmustâ€; however, the absolute requirement is that the axis position be stable and repeatable.
The mark may stabilize somewhat left or right (drift) of the vertical 
meridian and still enable you to ï¬  t a toric lens for that eye, as long as the lens always returns to the same â€œdrift axisâ€ position after settling. The deviation can be compensated for in the ï¬  nal prescription. Your objective is to ensure that whatever position the initial lens assumes near 6 oâ€™clock, this position must be stable and repeatable. With full eye movement or heavy blink, you may see the marks swing away, but they must return quickly to the original stable position. If the lens does not return quickly, you may need to select a different lens.
3. Assessing Rotation
Imagine the eye as a clock dial and every hour represents a 30Â° interval. If the orientation mark of the initial lens stabilizes somewhat left or right of the vertical position, the ï¬  nal lens will orient on the eye with the same deviation. You can use an axis reticule in the slit lamp or use a line-scribed lens in a spectacle trial frame to measure or estimate the â€œdrift angleâ€ of the cylinder axis.
To compensate for this â€œdriftâ€, measure or estimate the â€œdriftâ€, then 
add or subtract it from the refractive axis to determine the correct cylinder axis. Use the LARS (Left Add, Right Subtract) method to determine which direction to compensate.
CR-6530, v 1.0  
 
Page 78 of 137JJVC CONFIDENTIAL
B. Final Lens Power 
When the diagnostic lens has its axis aligned in the same meridian 
as the patientâ€™s refractive axis, a spherocylindrical over-refraction may be performed and visual acuity determined. However, in the case of crossed axes, such as when the diagnostic lens axis is different from the spectacle cylinder axis, it is not advisable to perform a full spherocylindrical over-refraction because of the difï¬  culty in computing the resultant power. A spherical over-refraction without cylinder refraction may be performed. 
If the required cylinder correction falls between two available cylinder 
powers, it is recommended to prescribe the lower cylinder power lens. See below for instructions on how to determine the ï¬  nal lens power.
1. For the Sphere
If sphere alone or combined sphere and cylinder Rx > Â±4.00D, 
compensate for vertex distance. If sphere alone or combined sphere and cylinder Rx â‰¤ Â±4.00D, vertex compensation is not necessary.
2. For the Cylinder
Adjust the axis by [CONTACT_35564]. Choose a cylinder that is â‰¤ 0.50D from the refractive cylinder.
3. Case Examples
Example [ADDRESS_385231] (spectacle) refraction:
O.D. -2.50D / -1.25D x 180Â° 20/20O.S. -2.00D / -1.00D x 180Â° 20/20
Choose a diagnostic lens for each eye with axis 180Â°. Place 
the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patientâ€™s initial response to the lens. If the lens has not yet stabilized, recheck until stable.
Check the orientation of the axis mark. If the bottom axis mark 
is in the 6 oâ€™clock position on both eyes, choose the appropriate cylinder as listed previously. If the lens has not yet stabilized, recheck until stable.
Here is the Rx Prescribed:
O.D. -2.50D / -1.25D x 180Â°O.S. -2.00D / -0.75D x 180Â°
CR-6530, v 1.[ADDRESS_385232] (spectacle) refraction:O.D. -3.00D / -1.00D x 90Â° 20/20O.S. -4.75D / -2.00D x 90Â° 20/20
Choose diagnostic lenses of -3.00D / -0.75D x 90Â° for the right 
eye and -4.50D / -1.75D x 90Â° for the left eye, the nearest lenses available to the spherical power, cylinder power, and axis needed. For the left eye, since the manifest refraction called for -4.75D, compensating for vertex distance the sphere is reduced by 0.25D to -4.50D. The cylinder power will be -1.75D. Place the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient's initial response to the lens. If the lens has not yet stabilized, recheck until stable. 
Right Eye
The orientation mark on the right lens rotates left from the 6 
oâ€™clock position by 10Â° and remains stable in this position. Compensation for this rotation should be done as follows: 
Compensate the 10Â° axis drift by [CONTACT_35565].
Here is the Rx Prescribed:
O.D. -3.00D / -0.75D x 100Â°
Left Eye
The orientation mark on the left lens rotates right from the 6 
oâ€™clock position by 10Â° and remains stable in this position. 
Compensate for the 10Â° axis drift by [CONTACT_35566]. 
Here is the Rx Prescribed: 
O.S. -4.50D / -1.75D x 80Â°
If vision is acceptable, perform a slit lamp examination to assess 
adequate ï¬  t (centration and movement). If ï¬  t is acceptable, dispense the lenses instructing the patient to return in one week for reassessment (see dispensing and follow-up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. Copi[INVESTIGATOR_35461].acuvue.com.
CR-6530, v 1.[ADDRESS_385233] adequately 
corrected distance and near visual acuity in each eye. The amblyopic patient or the patient with signiï¬  cant astigmatism (greater than 1.00D) in one eye may not be a good candidate for monovision correction with these lenses.
Occupational and environmental visual demands should be 
considered. If the patient requires critical vision (visual acuity and stereopsis), it should be determined by [CONTACT_71190]. Monovision contact [CONTACT_35568]:
â€¢ visually demanding situations such as operating potentially 
dangerous machinery or performing other potentially hazardous 
activities; and
â€¢ driving automobiles (e.g., driving at night). Patients who cannot 
meet state driver's licensing requirements with monovision correction should be advised to not drive with this correction, OR may require that additional over-correction be prescribed.
2. Patient Education
All patients do not function equally well with monovision correc-tion. Patients may not perform as well for certain tasks with this correction as they have with spectacles (multifocal, bifocal, trifocal, readers, progressives). Each patient should understand that monovision, as well as other presby[CONTACT_35569], can create a vision compromise that may reduce visual acuity and depth perception for distance and near tasks. Therefore, caution should be exercised when the patient is wearing the correction for the ï¬  rst time until they are familiar with the vision provided in visually chal-lenging environments (e.g., reading a menu in a dim restaurant, driving at night in rainy/foggy conditions, etc.). During the ï¬  tting process, it is necessary for the patient to realize the disadvantages as well as the advantages of clear near vision and straight ahead and upward gaze that monovision contact [CONTACT_35570].
CR-6530, v 1.0  
 
Page 81 of 137JJVC CONFIDENTIAL
B. Eye Selection
1. Ocular Preference Determination Methods
Generally, the non-dominant eye is corrected for near vision. The 
following two methods for eye dominance can be used.
Method 1:  Determine which eye is the â€œsighting eye.â€ Have the 
patient point to an object at the far end of the room. 
Cover one eye. If the patient is still pointing directly at the object, the eye being used is the dominant (sighting) eye.
Method 2:  Determine which eye will accept the added power with 
the least reduction in vision. Place a hand-held trial lens equal to the spectacle near ADD in front of one eye and then the other while the distance refractive error correction is in place for both eyes. Determine whether the patient functions best with the near ADD lens over the right or left eye.
2. Other Eye Selection Methods
Other methods include the "Refractive Error Method" and the "Visual Demands Method."
Refractive Error MethodFor anisometropic correction, it is generally best to ï¬  t the more 
hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near.
Visual Demands Method
Consider the patientâ€™s occupation during the eye selection process 
to determine the critical vision requirements. If a patientâ€™s gaze for near tasks is usually in one direction, correct the eye on that side for near.
Example: A secretary who places copy to the left side of the desk 
will function best with the near lens on the left eye.
C. Special Fitting Characteristics
1. Unilateral Vision Correction
There are circumstances where only one contact [CONTACT_35571]. As an example, an emmetropic patient would only require a near lens, whereas a bilateral myope would require corrective lenses on 
CR-6530, v 1.0  
 
Page 82 of 137JJVC CONFIDENTIAL
both eyes.
Examples: A presby[CONTACT_35572] a +1.75D ADD 
would have a +1.75D lens on the near eye and the other eye left without correction. 
A presby[CONTACT_35573] a +1.50D ADD who is -2.50D 
myopic in the right eye and -1.50D myopic in the left eye may have the right eye corrected for distance and the left uncorrected for near.
2. Near ADD Determination
Always prescribe the lens power for the near eye that provides optimal near acuity at the midpoint of the patientâ€™s habitual reading distance. However, when more than one power provides optimal reading performance, prescribe the least plus (most minus) of the powers.
3. Trial Lens Fitting
A trial ï¬  tting is performed in the ofï¬  ce to allow the patient to experience monovision correction. Lenses are ï¬  t according to the GENERAL FITTING GUIDELINES for base curve selection described in this Package Insert.
Case history and standard clinical evaluation procedure should 
be used to determine the prognosis. Determine the distance correction and the near correction. Next determine the near ADD. With trial lenses of the proper power in place, observe the reaction to this mode of correction.
Allow the lenses to settle for about [ADDRESS_385234] the patient look at you. Assess the patientâ€™s reaction to distance vision under these circumstances. Then have the patient look at familiar near objects such as a watch face or ï¬  ngernails. Again assess the reaction. As the patient continues to look around the room at both near and distance objects, observe the reactions. Only after these vision tests are completed should the patient be asked to read print. Evaluate the patientâ€™s reaction to large print (e.g., typewritten copy) at ï¬  rst and then graduate to newsprint and ï¬  nally smaller type sizes.
After the patientâ€™s performance under the above conditions 
is completed, tests of visual acuity and reading ability under 
CR-6530, v 1.[ADDRESS_385235] several weeks of wear (when adaptation is occurring), it may be advisable for the patient to only drive during optimal driving conditions. After adaptation and success with these activities, the patient should be able to drive under other conditions with caution.
D. Other Suggestions
The success of the monovision technique may be further improved by [CONTACT_35574]:
â€¢ Have a third contact [CONTACT_13293] (distance power) to use when critical 
distance viewing is needed.
â€¢ Have a third contact [CONTACT_13293] (near power) to use when critical near 
viewing is needed.
â€¢ Having supplemental spectacles to wear over the monovision 
contact [CONTACT_35575]ï¬  c visual tasks may improve the success of monovision correction. This is particularly applicable for those patients who cannot meet state driver's licensing requirements with monovision correction.
â€¢ Make use of proper illumination when carrying out visual tasks.
CR-6530, v 1.0  
 
Page 84 of 137JJVC CONFIDENTIAL
Monovision ï¬  tting success can be improved by [CONTACT_35576]:
â€¢ Reverse the distance and near eyes if a patient is having trouble 
adapting.
â€¢ Reï¬  ne the lens powers if there is trouble with adaptation. 
Accurate lens power is critical for presby[CONTACT_35577].
â€¢ Emphasize the beneï¬  ts of clear near vision and straight ahead 
and upward gaze with monovision.
The decision to ï¬  t a patient with monovision correction is most appropriately left to the Eye Care Professional in conjunction with the patient after carefully considering the patientâ€™s needs.
All patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copi[INVESTIGATOR_35461].acuvue.com.
PATIENT MANAGEMENT
Dispensing Visit
Each sterile lens is supplied in a foil-sealed plastic package containing 
buffered saline solution with methyl ether cellulose. To remove the lens from the container, peel back the foil seal, place a ï¬  nger on the lens, and slide the lens up the side of the bowl of the lens package until it is free of the container.
â€¢ Evaluate the physical ï¬  t and visual acuity of the lens on each eye.
â€¢ Teach the patient how to apply and remove his or her lenses.
â€¢ Explain daily disposable lens wear and schedule a follow-up examination.
â€¢ Provide the patient with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copi[INVESTIGATOR_35461].acuvue.com.
REVIEW THESE INSTRUCTIONS WITH THE PATIENT SO THAT HE 
OR SHE CLEARLY UNDERSTANDS THE PRESCRIBED WEARING AND REPLACEMENT SCHEDULES.
Follow-Up Examinations
Follow-up care (necessary to ensure continued successful contact [CONTACT_13279]) should include routine periodic progress examinations, management of speciï¬  c problems, if any, and a review with the patient of the wear schedule, daily disposable modality, and proper lens handling procedures. 
CR-6530, v 1.0  
 
Page 85 of 137JJVC CONFIDENTIAL
Recommended Follow-up Examination Schedule (complications 
and speciï¬  c problems should be managed on an individual patient 
basis):
1. One week from the initial lens dispensing to patient
2. One month post-dispensing
3. Every three to six months thereafter 
NOTE: Preferably, at the follow-up visits, lenses should be worn for at least 
six hours.
Recommended Procedures for Follow-up Visits:
1. Solicit and record patientâ€™s symptoms, if any.
2. Measure visual acuity monocularly and binocularly at distance and 
near with the contact [CONTACT_13276].
3. Perform an over-refraction at distance and near to check for residual 
refractive error.
4. With the biomicroscope, judge the lens ï¬  tting characteristics (as 
described in the GENERAL FITTING GUIDELINES) and evaluate 
the lens surface for deposits and damage.
5. Following lens removal, examine the cornea and conjunctiva with 
the biomicroscope and ï¬‚  uorescein (unless contraindicated).
â€¢ The presence of vertical corneal striae in the posterior central 
cornea and/or corneal neovascularization is indicative of 
excessive corneal edema.
â€¢ The presence of corneal staining and/or limbal-conjunctival 
hyperemia can be indicative of an unclean lens, a reaction to solution preservatives, excessive lens wear and/or a poorly ï¬  tting lens.
â€¢ Papi[INVESTIGATOR_35465]/or damaged lens.
6. Periodically perform keratometry and spectacle refractions. The 
values should be recorded and compared to the baseline meas-
urements.
If any observations are abnormal, use professional judgment to 
alleviate the problem and restore the eye to optimal conditions. If 
CR-6530, v 1.[ADDRESS_385236] spare lenses or spectacles available.
Basic Instructions
â€¢ Always wash, rinse, and dry hands before handling contact [CONTACT_13276].
â€¢ Do not use saliva or anything other than the recommended solutions 
for lubricating or rewetting lenses. Do not put lenses in the mouth.
â€¢ Eye Care Professionals may recommend a lubricating/rewetting solution which can be used to wet (lubricate) lenses while they are being worn to make them more comfortable. 
Care for a Sticking (Non-Moving) Lens
If the lens sticks (stops moving), the patient should be instructed to apply 
a few drops of the recommended lubricating or rewetting solution directly to the eye and wait until the lens begins to move freely on the eye before removing it. If non-movement of the lens continues after a few minutes, the patient should immediately consult the Eye Care Professional.
EMERGENCIES
The patient should be informed that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY WITH TAP WATER AND IMMEDIATELY CONTACT [CONTACT_35581] A HOSPI[INVESTIGATOR_35466]. 
HOW SUPPLIED
Each UV-blocking sterile lens is supplied in a foil-sealed plastic package containing buffered saline solution with methyl ether cellulose. The plastic package is marked with the following: 
â€¢ ACUVUE OASYS
Â® 1-Day: base curve, power, diameter, lot number, 
and expi[INVESTIGATOR_320]
â€¢ ACUVUE OASYSÂ® 1-Day for ASTIGMATISM: base curve, power, 
diameter, cylinder, axis, lot number, and expi[INVESTIGATOR_71159]-6530, v 1.0  
 
Page 88 of 137JJVC CONFIDENTIAL
REPORTING OF ADVERSE REACTIONS
All serious adverse experiences and adverse reactions observed in 
patients wearing these lenses or experienced with these lenses should be reported to:
[COMPANY_012] Vision Care, Inc.
[ADDRESS_385237]
Jacksonville, FL [ZIP_CODE]
[LOCATION_003]
Tel: [PHONE_564]
www.acuvue.com
CR-6530, v 1.0  
 
Page 89 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 APPENDIX D:   
x  LENS FITTING CHARACTERISTICS 
x  SUBJECT-REPORTED OCULAR SYMPTOMS 
x  DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTION 
x  BIOMICROSCOPY SCALE  
x  DISTANCE AND NEAR VISU AL ACUITY EVALUATION  
x  TORIC FIT EVALUATION 
x  LENS INSERTION AND REMOVAL 
                  
 
   
 
CR-6530, v 1.0  
 
Page 91 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
  LENS FITTING CHARACTERISTICS 
  
CR-6530, v 1.0  
 
Page 92 of 137JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:       
Document Number: Revision Number:  6 
CR-6530, v 1.0  
 
Page 96 of 137JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:       
Document Number: Revision Number:  6 
CR-6530, v 1.0  
 
Page 97 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 SUBJECT-REPORTED OCULAR SYMPTOMS 
  
CR-6530, v 1.0  
 
Page 98 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
  DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTION 
  
CR-6530, v 1.0  
 
Page 100 of 137JJVC CONFIDENTIAL
Title:                        Determination of Distance Spherocylindrical Refractive Error
Document Type:       
Document Number: Revision Number:  5 
      
CR-6530, v 1.0  
 
Page 102 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
  BIOMICROSCOPY SCALE  
  
CR-6530, v 1.0  
 
Page 106 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 DISTANCE AND NEAR VISUAL  ACUITY EVALUATION  
  
CR-6530, v 1.0  
 
Page 112 of 137JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:       
Document Number: Revision Number:  5 
CR-6530, v 1.0  
 
Page 114 of 137JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:       
Document Number: Revision Number:  5 
CR-6530, v 1.0  
 
Page 116 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 TORIC FIT EVALUATION 
  
CR-6530, v 1.0  
 
Page 117 of 137JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:       
Document Number: Revision Number:  7 
CR-6530, v 1.0  
 
Page 119 of 137JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:       
Document Number: Revision Number:  7 
      
CR-6530, v 1.0  
 
Page 121 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
  LENS INSERTION AND REMOVAL  
  
CR-6530, v 1.0  
 
Page 122 of 137JJVC CONFIDENTIAL
Title:     Lens Insertion and Removal 
Document Type:  
Document Number:  Revision Number:  3 
  
   
 
  
 
CR-6530, v 1.0  
 
Page 124 of 137JJVC CONFIDENTIAL
Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc.  
 
 
 
 APPENDIX E:  GUIDELINES FOR COVID-19 RISK MITIGATION 
  
CR-6530, v 1.0  
 
Page 125 of 137JJVC CONFIDENTIAL
 Clinical Study Protocol 
[COMPANY_012] Vision Care, Inc. 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE [CONTACT_169778]: CR-6530 Eval uation of ACUVUEÂ® OASYS 1-Day for 
Astigmatism Contact [CONTACT_312808]: 1.0 1  January [ADDRESS_385238] this study according to ISO [ZIP_CODE]:2020,1 the Declaration of Helsinki,2 
[LOCATION_002] (US) Code of  Federal Regulations (CFR),3 and the pertinent individual country 
laws/regulations and to comply with its obligations, subject to ethical and safety 
considerations. I, as the Principal Investigator, am  responsible for ensuring that all clinical site 
personnel, including Sub-Investigators, adhere to all regulations and GCP guidelines regarding 
clinical trials during and after study completion. 
I will assure that no deviation from or changes to the protocol will take place without prior 
agreement from the Sponsor and documented approval from the Instit utional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All clinical site personnel involved in the conduct of this study have completed Human 
Subjects Protection Training.  I agree to ensure that all clinical site pe rsonnel involved in the conduct of this study are 
informed about their obligations in  meeting the above commitments. 
I shall not disclose the information contained in th is protocol or any results obtained from this 
study without written authorization. I have read the suggested guidance provide d by [CONTACT_19610]-19 risk 
mitigation, (COVID-19 Work Instruction in th e Appendix E of this protocol). I agree to 
conduct this study in compliance with local, state, governmental  guidance for COVID-19 risks. 
Principal 
Investi
gator: 
Signature [CONTACT_312810] (Printed) 
Institution/Site: 
Institution/Site Name 
[CONTACT_16277]/Site Address 
CR-6530, v 1.0  
Page 137 of 137JJVC CONFIDENTIAL